Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/788 426 INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT Jacques Dumas First Named Inventor Art Unit 1625 (Use as many sheets as necessary) Examiner Name Heidi L. Reese Sheet of 37 Attorney Docket Number BAYER-0044

Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Initials *	No	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	
	A1	502,504	08-01-1893	Thoms	
	A2	1,792,156	02-10-1931	Fitzky	
	А3	2,046,375	07-07-1936	Goldstein et al.	
	A4	2,093,265	09-14-1937	Coffey et al.	
	A5	2,288,422	06-30-1942	Rohm	
	A6	2,649,476	08-18-1953	Martin	
	A7	2,683,082	07-06-1954	Hill et al.	
	A8	2,722,544	11-01-1955	Martin	
	A9	2,745,874	05-15-1956	Schetty et al.	
	A10	2,781,330	02-12-1957	Downey	
	A11	2,797,214	06-25-1957	Bossard	
	A12	2,867,659	01-06-1959	Model et al.	
	A13	2,877,268	03-10-1959	Applegath et al.	
	A14	2,960,488	11-15-1960	Tamblyn et al.	
	A15	2,973,386	02-28-1961	Weldon	
	A16	3,151,023	09-29-1964	Martin	
	A17	3,200,035	08-10-1965	Martin et al.	
	A18	3,230,141	01-18-1966	Frick et al.	
	A19	3,284,433	11-08-1966	Becker et al.	
	A20	3,424,760	01-28-1969	Helsley et al.	
	A21	3,424,761	01-28-1969	Helsley et al.	
	A22	3,424,762	01-28-1969	Helsley	
	A23	3,547,940	12-15-1970	Brantley	
	A24	3,639,668	02-01-1972	Alles et al.	
	A25	3,646,059	02-29-1972	Brantley	
	A26	3,668,222	06-06-1972	Hauser	
	A27	3,689,550	09-05-1972	Schellenbaum et al	
	A28	3,743,498	07-03-1973	Brantley	
	A29	3,754,887	08-28-1973	Brantley	
	A30	3,823,161	07-09-1974	Lesser	
	A31	3,828,001	08-06-1974	Broad et al.	
	A32	3.860.645	01-14-1975	Nikawitz	
	A33	3,990,879	11-09-1976	Soper	
	A34	4,001,256	01-04-1977	Caliahan et al.	
	A35	4,009,847	03-01-1977	Aldrich et al	
	A36	4.042.372	08-16-1977	Harper	
	A37	4.062.861	12-13-1977	Yukinaga et al.	
	A37a	4.063.928	12-20-1977	Johnston	

EXAMINER Inhal If reference considered, whether or not obtains in in conformance with MFTP 600. Draw fine through, clation if not in conformance and not considered with the conformance and not considered and the conformance and not considered and the conformance and not considered and the conformance and not conformance and not considered and the conformance and not considered and the conformance and not conformance and not considered and the conformance and not considered and not conformance and not Alexandria, VA 22313-1450

Under the Paperwork Beduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

			111000	NOT FEE OF 1000, THE POTOGRAP OF	o roquirou so rooparia so a conocion on	mornador a rodo nocinar o a vara o mo consenior do	
	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
				CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
_	Sheet	2	of	37	Attorney Docket Number	BAYER-0044	

			U.S. PATENT I	DOCUMENTS	
Examiner Initials	Cite No 1	Document Number Number - Kind Gode ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan Passages or Relevant
	A38	4.071.524	01-31-1978	Banitt	Figures Appear
	A39	4.103,022	07-25-1978	Sirrenberg et al	-
	A40	4,111.680	09-05-1978	Yukinaga et al.	
	A41	4,111,683	09-05-1978	Singer	
	A42	4,116,671	09-26-1978	Yukinaga et al.	
	A43	4,173,637	11-06-1979	Nishiyama et al.	
	A44	4,173,638	11-06-1979	Nishiyama et al.	
	A45	4,173,636	01-15-1980	Crossley	
	A45	4,163,654	07-15-1980	Yukinaga et al.	
	A47	4,212,901	12-23-1980	Dickore et al.	
	A47 A48	4,240,820	07-21-1981	Okamoto et al.	
	A48a	4,279,039	10-06-1981		
		.,,		Yukinaga et al.	
	A49	4,358,596	11-09-1982	Krüger	
	A50	4,405,644	09-20-1983	Kabbe et al.	
	A51	4,410,697	10-18-1983	Török et al.	
	A52	4,437,878	03-20-1984	Acker et al.	
	A53	4,468,380	08-28-1984	O'Doherty et al.	
	A54	4,473,579	09-25-1984	Devries et al.	
	A55	4,499,097	02-12-1985	Tomoufcik et al.	
	A56	4,511,571	04-16-1985	Böger et al.	
	A57	4,514,571	04-30-1985	Nakai et al.	
	A58	4,526,997	07-02-1985	O'Doherty et al.	
	A59	4,540,566	09-10-1985	Davis et al	
	A60	4,546,191	10-08-1985	Nishiyama et al	
	A61	4,587,240	05-06-1986	Hider et al.	
	A62	4,623,662	11-18-1986	DeVries	
	A63	4,643,849	02-17-1987	Hirai et al.	
	A64	4,740,520	04-26-1988	Hallenbach et al.	
	A65	4,760,063	07-26-1988	Hallenbsch et al.	
	A66	4,775,763	10-04-1988	Dalton et al.	
	A67	4,808,588	02-28-1989	King	
	A68	4.820.871	04-11-1989	Kissener et al.	
	A69	4,863,924	09-05-1989	Haga et al.	
	A69a	4,921,525	05-01-1990	Grossman et al.	
	A70	4,973,675	11-27-1990	Israel et al.	
	A70a	4,977,169	12-11-1990	Häusermann et al.	
	A71	4,983,605	01-08-1991	Kondo et al	
	A72	4,985,449	01-15-1991	Haga et al.	
	A72a	4 996 325	02-26-1991	Kristinsson	

Considered

Signature

This I reference considered, whether or not delice is not extensive to the contract of the con Alexandria, VA 22313-1450.

	$\overline{}$	Uldel tie raperwo	IK HBUUI	AUT ACTOL 1995, HO DetSOLIS all	required to respond to a conscitor for it	TOTALIOT OF 1988 IT COTTAINS A VAIIG CIVID COTTO HUTTON	
	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
ུ	Sheet	3	of	37	Attorney Docket Number	BAYER-0044	

			U.S. PATENT I	OCUMENTS	
Examiner Initials *	Cite No	Document Number Number - Kind Gode ² (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A73	5.036.072	07-30-1991	Nakajima et al.	Figures Appear
	A74	5.059,614	10-22-1991	Lepage et al.	
	A75	5,063.247	11-05-1991	Sekiya et al.	
	A76	5.098.907	03-24-1992	Kondo et al	
	A77	5.100.883	03-31-1992	Schiehser	
	A78	5.118.677	06-02-1992	Caufield	
	A79	5.118.678	06-02-1992	Kao et al	
	A80	5,120,842	06-09-1992	Failli et al.	
	A81	5,130,331	07-14-1992	Pascual	
	A82	5.151.344	09-29-1992	Abe et al.	
	A83	5,151,413	09-29-1992	Caufield et al.	
	A84	5,162,360	11-10-1992	Creswell et al.	
	A84a	5,177,110	01-05-1993	Oechslein et al.	
	A85	5.185.358	02-09-1993	Creswell et al.	
	A86	5,256,790	10-26-1993	Nelson	
	A87	5,258,389	11-02-1993	Goulet et al.	
	A88	5,270,458	12-14-1993	Lemischka	
	A89	5,283,354	02-01-1994	Lemischka	
	A90	5,312,820	05-17-1994	Ashton et al.	
	A91	5,319,099	08-07-1994	Kamata et al.	
	A92	5,378,725	01-03-1995	Bonjouklian et al.	
	A93	5,399,566	03-21-1995	Katano et al	
	A94	5,423,905	06-13-1995	Fringeli	
	A95	5,429,918	07-04-1995	Seto et al.	
	A96	5,432,463	07-11-1995	Moriyama et al.	
	A97	5,441,947	08-15-1995	Dodge et al.	
	A98	5,447,957	09-05-1995	Adams et al.	
	A99	5,456,920	10-10-1995	Matoba et al	
	A100	5.468.773	11-21-1995	Dodge et al.	
	A101	5,470,882	11-28-1995	Dixon et al.	
	A102	5,480,906	01-02-1996	Creemer et al.	
	A103	5.500.424	03-19-1996	Nagamine et al.	
	A104	5,508,288	04-16-1996	Forbes et al.	
	A105	5,547,988	08-20-1996	Atwal et al.	
	A106	5,559,137	09-24-1996	Adams et al.	
	A107	5,596,001	01-21-1997	Hamanaka	
	A108	5,597,719	01-28-1997	Freed et ai	
	A109	5,624,937	04-29-1997	Reel et al.	
Examiner Signature				Date Considered	

Signature Considered

FAANINER Initial interence considered, whether or not classion is in conformance with MEP 500 Dress line strongly classion if not in conformance and not considered include copy of this form with next communication to applicant. "Applicant" suspectations designation number (optional). "See Kndd Codes of USFO Patent Documents at war applicant on the Conformation of the Comment of the Comm Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substit	ute for form 1449A/PT0)		Complete if Known		
				Application Number	10/788,426	
INF	ORMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
STA	TEMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Sheet 4 of 37		Attorney Docket Number	BAYER-0044			

Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials *	No 1	Number - Kind Gode ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
	A110	5,656,612	08-12-1997	Monia		
	A111	5,658,903	08-19-1997	Adams et al		
	A111a	5,667,226	09-16-1997	Janich		
	A112	5,696,138	12-09-1997	Olesen et al.		
	A113	5,698,581	12-16-1997	Kleemann et al		
	A114	5,710,094	01-20-1998	Minami et al.		
	A115	5,721,237	02-24-1998	Myers et al		
	A116	5,726,167	03-10-1998	Dodge et al.		
	A117	5,747,498	05-05-1998	Schnur et al.		
	A118	5,773,459	06-30-1998	Tang et al.		
	A119	5,777,097	07-07-1998	Lee et al.		
	A120	5,780,262	07-14-1998	Brent et al.		
	A121	5,780,483	07-14-1998	Widdowson et al.		
	A122	5,783,664	07-21-1998	Lee et al.		
	A123	5,786,362	07-28-1998	Krongrad		
	A123a	5,801,794	09-01-1998	Lehureau et al.		
	A124	5,807,876	09-15-1998	Armistead et al.		
	A125	5,807,891	09-15-1998	Bold et al.		
	A126	5,803,080	09-15-1998	Bell et al.		
	A127	5,814,646	09-29-1998	Heinz et al		
	A128	5,869,043	02-09-1999	McDonnell et al.		
	A129	5,871,934	02-16-1999	Lee et al.		
	A130	5,886,044	03-23-1999	Widdowson et al.		
	A131	5,891,895	04-06-1999	Shiraishi et al.		
	A132	5,908,865	06-01-1999	Doi et al.		
	A133	5,919,773	07-06-1999	Monia et al		
	A134	5,929,250	07-27-1999	Widdowson et al.		
	A135	5,955,366	09-21-1999	Lee et al.		
	A136	5,965,573	10-12-1999	Petrie et al.		
	A137	6,004,965	12-21-1999	Breu et al.		
	A138	6,005,008	12-21-1999	Widdowson et al.		
	A139	6,015,908	01-18-2000	Widdowson et al.		
	A140	6,017,692	01-25-2000	Brent et al.		
	A141	6,020,345	02-01-2000	Vacher et al.		
	A142	8,022,884	02-08-2000	Mantlo et al.	1	
	A143	6,025,151	02-15-2000	Peterson		
	A144	6,033,873	03-07-2000	McDonnell et al.		
	A145	6,040,339	03-21-2000	Yoshida et al.		
Examiner Signature				Date Considered		

Signature

Signature

Considered

Conside Alexandria, VA 22313-1450.

Approved for use through 11/30/2007. OMB 0551-030
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

_	Ulubi sib i apoiwo	IIK I IBGG	AUT AUX UT 1880, HU person is all	s required to respond to a conscitor for it	IIO ITADO EL 1988 IL COLIDATE A VAIG CIVID COLIDO TOTTO DE	
Substit	tute for form 1449A/PTC)		Complete if Known		
				Application Number	10/788,426	
	ORMATION			Filing Date	March 1, 2004	
ST	ATEMENT B	Y A	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	eets as	necessary)	Examiner Name	Heidi L. Reese	
Sheet	5	of	37	Attorney Docket Number	BAYER-0044	

	_		U.S. PATENT I			
Examiner Initials *	Cite No 1	Document Number Number - Kind Gode ² (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Oiled Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A110	5,656,612	08-12-1997	Monia		
	A111	5,658,903	08-19-1997	Adams et al.		
	A146	6,043,374	03-28-2000	Widdowson et al		
	A147	6,080,763	06-27-2000	Regan et al.		
	A148	6,093,742	07-25-2000	Salituro et al		
	A149	6,103,692	08-15-2000	Avruch et ai.		
	A150	6,114,517	09-05-2000	Monia et al		
	A151	6,130,053	10-10-2000	Thompson et al.		
	A152	6,133,319	10-17-2000	Widdowson		
	A153	6,136,779	10-24-2000	Foulkes et al.		
	A154	6,143,764	11-07-2000	Kubo et al.		
	A155	6,147,107	11-14-2000	Dent et al.		
	A156	6,147,116	11-14-2000	Barbachyn et al.		
	A157	6.150.415	11-21-2000	Hammock et al.		
	A157a	6,159,901	12-12-2000	Kanno et al		
	A158	6.174.901	01-16-2001	Mantlo et al.		
	A159	6.177.401	01-23-2001	Ullrich et al.		
	A160	6,178,399	01-23-2001	Takebayashi et al.		
	A161	6,180,631	01-30-2001	McMahon et al.		
	A162	6,180,675	01-30-2001	Widdowson et al.		
	A163	6,187,799	02-13-2001	Wood et al.		
	A164	6,193,965	02-27-2001	Karin et al.		
	A165	6,204,267	03-20-2001	Tang et al		
	A166	6,210,710	04-03-2001	Skinner		
	A167	6,211,373	04-03-2001	Widdowson et al		
	A168	6,218,539	04-17-2001	Widdowson		
	A169	6,228,881	05-08-2001	Regan et al.		
	A170	6,235,764	05-22-2001	Larson et al.		
	A170a	6,236,125	05-22-2001	Oudet et al		
	A171	6,242,601	06-05-2001	Breu et al.		
	A172	6,262,113	07-17-2001	Widdowson et al.		
	A173	6.271.261	08-07-2001	Widdowson		
	A174	6,294,350	09-25-2001	Peterson		
	A175	6,297,381	10-02-2001	Cirillo et al.		
	A176	6,310,068	10-30-2001	Böttcher et al.		
	A177	6,316,462	11-13-2001	Bishop et al.		
	A178	6,319,921	11-20-2001	Ciritlo et al.		
	A179	6,329,415	12-11-2001	Cirillo et al.		

"EXAMINER final if reference considered, whether or not dation is in conformance with MFFE 80D. Draw lime through dation if not in conformance and not considered include copy of the form with neat communication to applicant." Applicant's usage dations designation mamber (optional). "See Reinds Cooles of USFO Patient Documents as assurance of the PEPT 00.01." Listed Potential in since the deconvent by the level lime of the Victor of WIPTO Standard ST 31. For spacement and dations of the declared of the discussed in the discussed

This collection of information is equived by 37 CPF1 ff 39 and TBS. The information is required to detain or detain as breaft by the juddes which is 10 ft field by the LUPFC (but and an advanting the exception of the property of the public which is 10 ft field by the LUPFC (but and advanting the exception of the public which is 10 ft field by the LUPFC (but and advanting the exception of the public which is 10 ft field by the LUPFC (but and advanting the exception of the public which is 10 ft field by the LUPFC (but and advanting the public which is 10 ft field by the LUPFC (but and advanting the luminosis of t

	_	Unide the Labernio	IK I IDGU	COULT PLC OF 1000, HO porsonio al	s required to respond to a conscitor for	HIGH Hallot full 1986 It Cortains a valid Civid Cortain united
(Substitute	for form 1449A/PTC)			Complete if Known
					Application Number	10/788,426
				CLOSURE	Filing Date	March 1, 2004
	STAT	TEMENT B	YΑ	PPLICANT	First Named Inventor	Jacques Dumas
					Art Unit	1625
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese
Z	Sheet	6	of	37	Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS								
Examiner Initials *	Cite No	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant			
iiiiiiab	-	Number - Kind Gode ² (if known)			Figures Appear			
	A180	6,333,341	12-25-2001	Mantlo et al.				
	A181	6,339,045	01-15-2002	Kanno et al				
	A182	6,344,476	02-05-2002	Ranges et al.				
	A183	6,352,977	03-05-2002	Astles et al				
	A184	6,358,525	03-19-2002	Guo et al.				
	A185	6,358,945	03-19-2002	Breitfelder et al.				
	A186	6,361,773	03-26-2002	Lee et al.				
	A187	6,372,773	04-16-2002	Regan				
	A188	6,372,933	04-16-2002	Baine et al				
	A189	6,380,218	04-30-2002	Marfat et al.				
	A190	6,383,734	05-07-2002	Marshall et al.				
	A191	6,387,900	05-14-2002	Pevarello et al.				
	A192	6,391,917	05-21-2002	Petrie et al				
	A193	6,403,588	06-11-2002	Hayakawa et al.				
	A194	6,414,011	07-02-2002	Hogenkamp et al.				
	A195	6,444,691	09-03-2002	Oremus et al.				
	A196	6,448,079	09-10-2002	Monia et al.				
	A197	6,479,519	11-12-2002	Astles et al				
	A198	6,492,393	12-10-2002	Breitfelder et al.				
	A199	6,495,331	12-17-2002	Gelfand et al.				
	A200	6,500,863	12-31-2002	Jin et al.				
	A201	6,511,800	01-28-2003	Singh				
	A202	6,511,997	01-28-2003	Minami et al.				
	A203	6,521,407	02-18-2003	Warenius et al				
	A204	6,521,592	02-18-2003	Ko et al.				
	A205	6,524,832	02-25-2003	Kufe et al.				
	A206	6,525,046	02-25-2003	Cirillo et al.				
	A207	6,525,065	02-25-2003	Caldwell et al.				
	A208	6,525,091	02-25-2003	Robinson et al.				
	A209	6,583,282	06-24-2003	Zhang et al.				
	A210	6,608,052	08-19-2003	Breitfelder et al.				
	A211	6,617,324	09-09-2003	Naraian et al.				
	A212	6,635,421	10-21-2003	Klagsbrun et al.				
	A213	6,653,320	11-25-2003	Hayakawa et al.				
	A214	8,858,983	12-02-2003	Firestone et al.				
	A215	6,673,777	01-06-2004	Tracey et al.				
	A216	6,689,560	02-10-2004	Rapp et al.				
	A217	6,797,323	09-28-2004	Kubo et al.				
Examiner Signature				Date Considered				

Signature

Considered

Conside Alexandria, VA 22313-1450.

PTO/SB/08a (11-07)
Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE approach to a cylindron of information.

	$\overline{}$	Under the Laborato	IK I IBGO	AUTHA O 1990, NO persona a	e required to respond to a conscitor of	Indinator or less it contains a valid DIVIB control fur full			
(Substitute	for form 1449A/PTC)			Complete if Known			
					Application Number	10/788,426			
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004			
	STAT	EMENT B	YΑ	PPLICANT	First Named Inventor	Jacques Dumas			
					Art Unit	1625			
	(Use as many sheets as necessary)				Examiner Name	Heidi L. Reese			
Z	Sheet 7 of 37		Attorney Docket Number	BAYER-0044					
г	HO DATENT DOCUMENTO								

Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevan	
Initials *	No 1	Number - Kind Code ² (#known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
	A217a	6,958,333	10-25-2005	Hayama et al.		
	A218	7,070,968	07-04-2006	Kufe et al		
	A219	7,235,576	06-26-2007	Riedi et al.		
	A220	7,253,286	08-07-2007	Funahashi et al		
	A221	7,307,071	12-11-2007	Lyons et al.		
	A222	7,329,670	02-12-2008	Dumas et al.		
	A223	7,351,834	04-01-2008	Riedi et al.		
	A224	7,371,763	05-13-2008	Dumas et al.		
	A225	7,517,880	04-14-2009	Miller et al.		
	A226	7,528,255	05-05-2009	Riedi et al.		
	A226a	7,547,695	06-16-2009	Hoelzemann et al.		
	A227	7,557,129	07-07-2009	Scott et al		
	A227a	7,605,261	10-20-2009	Deprez et al.		
	A227 b	7,612,092	11-03-2009	Funahashi et al		
	A228	7,678,811	03-16-2010	Dumas et al.		
	B1	2001/0006975	07-05-2001	Wood et al		
	B2	2001/0011135	08-02-2001	Riedl et al.		
	B3	2001/0011136	08-02-2001	Riedl et al.		
	B4	2001/0016659	08-23-2001	Riedl et al.		
	85	2001/0027202	10-04-2001	Riedl et al		
	B6	2001/0034447	10-25-2001	Riedl et al.		
	B7	2001/0038842	11-08-2001	Achen et al.		
	B8	2002/0037276	03-28-2002	Ptasznik et al.		
	B9	2002/0042517	04-11-2002	Uday et al		
	B10	2002/0062763	05-30-2002	Macholdt et al.		
	B11	2002/0065283	05-30-2002	McMahon et al		
	B12	2002/0065296	05-30-2002	Dumas et al		
	B13	2002/0032255	06-27-2002	Eastwood		
	B14	2002/0085857	07-04-2002	Kim et al.		
	B15	2002/0085859	07-04-2002	Hashimoto et al.		
	B16	2002/0103253	08-01-2002	Ranges et al.		
	B16a	2002/0111495	08-15-2002	Magee et al.		
	B17	2002/0128321	09-12-2002	Widdowson et al		
	B18	2002/0137774	09-26-2002	Riedt et at.		
	B19	2002/0161014	10-31-2002	Sadhu et al		
	B20	2002/0165275	11-07-2002	Wu et al.		

EVANINGE fields if reference considered, whether or not distinn is in conformance with MFPE 600 Draw line through citation if not in conformance and not considered include copy of this form with not communication to applicant. Applicant's useas catalons designation number (spotcing). See Nede Cockes of USFTO Patent Documents are with the communication of the proper rising because the conformation of the proper rising because the sense in market of the proper rising because the sense in market of the patent document. Fill we discharded ST 16 (possible. "Applicant is to place a check mark here of English Insegange Translation is allocated." This collection of intermediation is asked with the proper rising because the proper rising because

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

1	Substitute	for form 1449A/PTC)		Complete if Known				
					Application Number	10/788,426			
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004			
	STAT	TEMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas			
					Art Unit	1625			
	(Use as many sheets as necessary)				Examiner Name	Heidi L. Reese			
Z	Sheet 8 of 37		Attorney Docket Number	BAYER-0044					
_									

U.S. PATENT DOCUMENTS									
Examiner Initials *	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Gited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant				
Initials -	IVO	Number - Kind Gode ² (if known)	MMPDOTTTT		Figures Appear				
	B21	2002/0165349	11-07-2002	Kirsch et al.					
	822	2002/0165394	11-07-2002	Dumas et al					
	B23	2002/0173507	11-21-2002	Santora et al.					
B24 B25		2002/0188027	12-12-2002	Robinson et al.					
		2002/0197256	12-26-2002	Grewal					
	B26	2003/0069284	04-10-2003	Keegan et al.					
	B26e	2003/0105091	06-05-2003	Riedl et al.					
	B27	2003/0125359	07-03-2003	Lyons et al.					
	B28	2003/0130309	07-10-2003	Moss et al.					
	B29	2003/0144278	07-31-2003	Reidi et al.					
	B30	2003/0157104	08-21-2003	Waksal					
	B30a	2003/0139605	07-24-2003	Riedi et al					
	B31	2003/0181442	09-25-2003	Riedl et al					
	B32	2003/0207870	11-06-2003	Dumas et al.					
	B33	2003/0207872	11-06-2003	Reidl et al.					
	B34	2003/0207914	11-06-2003	Dumas et al.					
	B34a	2003/0216396	11-20-2003	Dumas et al.					
	B35	2003/0216446	11-20-2003	Dumas et al.					
	B36	2003/0232400	12-18-2003	Radka et al.					
	B37	2003/0232765	12-18-2003	Carter et al.					
	B37a	2004/0023981	02-05-2004	Dumas et al.					
	B38	2004/0052880	03-18-2004	Kobayashi et al					
	B39	2004/0096855	05-20-2004	Stratton et al.					
	B40	2004/0147541	07-29-2004	Lane et al.					
	B41	2004/0192770	09-30-2004	Kozikowski et al					
	B42	2004/0197256	10-07-2004	Rogers et al.					
	B43	2004/0209905	10-21-2004	Kubo et al					
	B43a	2004/0224937	11-11-2004	Furness et al.					
	B44	2004/0229937	11-18-2004	Dumas et al.	l				
	B45	2004/0235829	11-25-2004	Scott et al.					
	B46	2005/0032798	02-10-2005	Boyer et al					
	B47	2005/0038031	02-17-2005	Dumas et al.	i				
	B48	2005/0038080	02-17-2005	Boyer et al.	i				
	B49	2005/0059703	03-17-2005	Withelm et al.	l				
	B49a	2005/0069963	03-31-2005	Lokshin et al.	l				
	B49b	2005/0096344	05-05-2005	Fraley et al.					
	B49c	2005/0175737	08-11-2005	Knobel					
	B50	2005/0256174	11-17-2005	Wood et al					
Examiner Signature				Date Considered					

Signature

Considered

Conside Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

						Applie	cation Number	10/7	88,426
				CLOS		Filing	Date	Mar	ch 1, 2004
STA	TEME	ENT B	Y AI	PPLICA	ANT	First I	Named Inventor	Jaco	ues Dumas
						Art U	nit	162	5
	(Use as many sheets as necessary)					Exam	niner Name	Heio	li L. Reese
Sheet 9 of 37					Attorr	ney Docket Number	BAY	ER-0044	
U.S. PAT					U.S. PAT	ENT D	OCUMENTS		
Examiner	Gite	Doc	ument N	umber	Publication	Date	Name of Patentee or Applic	ant of	Pages, Columns, Lines, Where Relevant
Initials *	No	Number - Kind Gode ² (if known)		MM-DD-YYYY		Cited Document		Passages or Relevant Figures Appear	
	B51	201	05/0288	3286	12-29-2005 Flynn et al.		Flynn et al.		
	B52	201	06/0058	3358	03-16-20	03-16-2006 Dumas et al.			
	B52a	201	06/024	1301	10-26-20	10-26-2006 Hoelzemann et al.			
	B52b	20	06/028	1762	12-14-2006 Stashle et al.		Stashle et al.		
	B53	201	06/00 7 8	3617	04-13-29	006	Schueckler		
	B54	201	06/021	1738	09-21-20	006	Mitchell et al.		
	B55	20	06/0234	1931	10-19-20	006	Biggs. III et al.		
	B56	200	06/0247	7186	11-02-20	006	Carter et al.		
	B57 2007/0020704 01-25-20		07	Withelm et al.					
	B58	201	07/010	5142	05-10-20	007	Wilhelm		
	860	201	07/0178	3494	08-02-20	007	Elting et al.		
	B61	200	07/024	1120	10-18-20	007	Dumas et al		

Dumas et al

Dumas et al

Riedl et al

Riedi et al Kelley

Rigdl et al

Riedl et al

Lee et al

Dumas et a

Dumas et al

Million at all

Durnas et al

Eiting et al

Wilhelm

Miller et al

Right at at

Wilhelm

Scheuring et al

Schuckler et al.

11-15-2007

01-31-2008

02-21-2008

05-08-2008

06-26-2008

09-04-2008

09-18-2008

10,30,2008

12-04-2008

12-18-2008

12-18-2008

03-12-2009

04-09-2009

05-07-2000

07-90-9000

08-27-2009

Substitute for form 1449A/PTO

862

B63

B64

B65

867

B69

B70

B71

B73

B74

876

877

B77a

B77b

878

B79

Ban

pos

B84

2007/0265315

2008/0027061

2008/0032979

2008/0045589

2008/0108672

2008/0214545

2008/0227828

2008/0242707

2002/02/02/02

2008/0300281

2008/0311604

2009/0068146

2009/0093526

2009/01/18268

2009/0192127

2009/0215835

Examiner Signature				Date Considered		
	888	2010/0063033	03-11-2010	Wood et al.		
B86		2009/0306020	12-10-2009	Scheuring et al		
	B85	2009/0227637	09-10-2009	Weber et al.		
	B84a	2009/0221010	09-03-2009	Eiting et al.		

"EXAMINE: Initial Intellection considered, whether or not clation in a notiferance with IMEPT 600 their line through values in the incommence and of considered holds copy of the form with end commissionation to applicat." Application suggest actioned designation results of proposal "feet for followed 1957 0 Peter 10 Durantesia assessment of the proposal "feet for followed 1957 0 Peter 10 Durantesia assessment for the proposal "feet for followed 1957 0 Peter 10 Durantesia assessment for followed 1957 0 Peter 10 Durantesia assessment followed 1957 0 Peter 1957 0 Peter 1957 0 Peter 10 Durantesia assessment followed 1957 0 Peter 1957 0 Pe

process) an application Confidentiality is governed by 3 U S C 122 and 37 CFR 1 14. This collection is estimated to take 2 hours for complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any common to the amount of time you require to complete the form and/or suggestions for reducing this burden, should be sent to the Chief Information. US Platter and Indiamank Chief. Department of Committee, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	_	Under the haperwo	IK DBOOK	SIGN ACCOL 1995, NO persons an	e required to respond to a correction of it	normalion or less it contains a valid DIVIB control flumber	
	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STAT	LEMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
V	Sheet	Sheet 10 of 37		Attorney Docket Number	BAYER-0044		

Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
country code - Hamber - Hand code (Williams)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т6
WO-90/02112	03-08-1990	The Nutrasweet Company		
WO-92/03413	03-05-1992	Rhone-Roulenc Rorer Limited et al.		
WO-92/05179	04-02-1992	American Home Products Corporation		
WO-93/04170	03-04-1993	The United States of America represented by The Secretary, Department Of Health And Human Services		
WO-93/18028	09-16-1993	SmithKline Beecham PLC et al.		
WO-93/24458	12-09-1993	Pfizer Inc. et al.		
WO-94/02136	02-03-1994	SmithKline Beecham Corp. et al.		
WO-94/02485	02-03-1994	SmithKline Beecham Corp. et al.		
WO-94/04541	03-03-1994	The UpJohn Co. et al.		
WO-94/14801	07-07-1994	SmithKline Beecham PLC et al.		
WO-94/18170	08-18-1994	SmithKline Beecham PLC et al		
WO-94/22807	10-13-1994	Neu-Rosearch, A/S et al.		
WO-94/23755	10-27-1994	Board of Regents of the University of Nebraska		
WO-94/25012	11-10-1994	SmithKline Beecham PLC et al.		
WO-95/02136	01-19-1995	Mannesmann Akteingesellschaft		abs
3	WO-94/23755 WO-94/25012	WO-64/23755 10-27-1994 WO-64/25012 11-10-1994 WO-95/02136 01-19-1995 Date	WO-94/28755 10-27-1994 Control Regents Wo-94/28755 10-27-1994 Control Regents Wo-94/28012 11-10-1994 Beacham PLC et al. WO-95/02136 01-19-1995 Mannesmann Abtein-sessellight-all Abtein-sessellight-all Abtein-sessellight-all	WO-8425755 10-27-1998 Board of Regents of the University of Nebrasika WO-8425012 11-10-1994 Becamm PLC et al. WO-95/02136 O1-19-1998 Manneaman Akteinopaositischaft Date

Examine I Service I Servic Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

Substitu	te for form 1449A/PTC		300 F 100 OF 1000, NO POROOFE OF	Complete if Known		
				Application Number	10/788,426	
INFO	DRMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
STA	TEMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Sheet	Sheet 11 of 37		Attorney Docket Number	BAYER-0044		

SHeer	1.11	UI	3/		еу Боске		DATE	EN-0044	
			FOREIGN PA	ATENT	DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Country Code ² -	t Document Number ⁴ - Kind Code ⁶ (if known)		lication Date D-YYYY	Applica	Patentee or int of Cited current	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	C16		WO-95/02591	01-2	6-1995	SmithKlir Beecharr Corporati	1		
	C17		WO-95/079 22	03-2	3-1995	Smithklir Beecharr Corporati	on et al.		
	C18		WO-95/13067	05-1	8-1995	SmithKlir Beecham Corporati	i		
	C19		WO-95/14023	05-2	6-1995	Account La	boratories		
	C20		WO-95/16691	06-2	2-1995	Sandoz L	td. et al.		
	C21		WO-95/19169	07-2	0-1995	Sugen, Ir			
	C22		WO-95/31451	11-2	3-1995	Smithklin Beecharr Corporati	1		
	C23		WO-95/33458	12-1	4-1995	Smithklin Beecharr Corporati	on et al.		
	C24		WO-95/33460	12-1	4-1995	Smithxlin Beecharr Corporati	on et al.		
	C25		WO-96/02112	01-2	5-1996	Thomson al.	-CSF et		abs
	C26		WO-96/10559	04-1	1-1996	Fujisawa Pharmao Co Ltd			
	C27		WO-96/13632	05-0	9-1996	Novo Nor et al.	rdisk A/S		
	C28		WO-96/25157	08-2	2-1996	Smith Kli Beecharr Corporati	i		
	C29		WO-96/40673	12-1	9-1996	Sugen, Ir	ic.		
	C30		W0-96/40675	12-1	9-1996	Sugen. Ir	nc.		
	C31		WO-96/41807	12-2	7-1996	Sandoz L	.td. et al		
	C32		WO-97/03069	01-3	0-1997	Glaxe Gr Limited e			
	C33		WO-97/09973	03-2	0-1997	The Reg The Univ California	ersity of et al.		
	C34		WO-97/17267	05-1	5-15-1997 SCA Mörnlycke AB et al.				
	C35	WO-97/173 2 9		05-1	5-1997	Krin Bee Kabushik			abs
Examiner Signature					Date Consid	ered			

Examiner Signature

This collection of information is equivalently as of the collection of information is equivalent of the collection of information in contracts of the collection of information in included to the collection of information in contracts of information in included to the collection of information in contracts of information in contracts of information in included to the collection of information in contracts of information in included to the collection of information in contracts of information in contracts of information in included by the collection information in contracts of information in included by the collection information in inc Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute	for form 1449A/PTC)		Complete if Known			
INFORMATION DISCLOSURE					Application Number	10/788,426		
					Filing Date	March 1, 2004	_	
STATEMENT BY APPLICANT				PPLICANT	First Named Inventor	Jacques Dumas		
					Art Unit	1625		
(Use as many sheets as necessary)					Examiner Name	Heidi L. Reese		
	Sheet	12	of	37	Attorney Docket Number	BAYER-0044	j	

		0. 0,	Autoricy Doci		LIT 0044	
		FOR	EIGN PATENT DOC	UMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵	Publication Date (# known) MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
	C36	WO-97/29743	08-21-1997	Smith Kline Beecham Corporation et al.		
	C37	WO-97/30992	08-28-1997	Bristol-Myers Squibb Company		
	C38	WO-97/34146	09-18-1997	The General Hospital Corporation		
	C39	WO-97/40028	10-30-1997	Vertex Pharmaceuticals Incorporated		
	C40	WO-97/40842	11-06-1997	Eli Lilly and Company et al.		
	C41	WO-97/45400	12-04-1997	Neu-Rosearch A/S et al.		
	C42	WO-97/49399	12-31-1997	SmithKline Beecham Corporation et al.		
	C43	WO-97/49400	12-31-1997	SmithKline Beecham Corporation et al.		
	C44	WO-98/17207	04-30-1998	Synthes AG Chur et al.		
	C45	WO-98/17267	04-30-1998	Zymogenetics, Inc. et al.		
	C46	WO-98/20868	05-22-1998	The Picower Institute for Medical Research		
	C47	WO-98/22103	05-28-1998	Zeneca Limited et al.		
	C48	WO-98/22432	05-28-1998	Yamanouchi Pharmaceutical Co., Ltd.		abs
	C49	WO-98/32439	97-30-1998	SmithKline Beecham Corporation et al.		
	C50	WO-98/34929	08-13-1998	SmithKline Beecham Corporation et al.		
	C51	WO-98/45268	10-15-1998	Pfizer Products Inc. et al.		
	C52	WO-98/49150	11-05-1998	Takeda Chemical Industries, Ltd. et al.		

Signature Considered

Date

Examiner

EVALUATION THAT If reference considered, whether or no citation is in conformance with MEPF 600. Draw like the study, distinct if not in conformance and not considered with the conformance and not considered with the conformance in the conformance and not considered with the conformance in the conformance and not considered with the conformance in confo Alexandria, VA 22313-1450.

Under the Paperwork Beduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

						TOTAL OF A TOO OF TOTAL TO A VALID OF TO CONTO THE TIDE	
	Substitute	for form 1449A/PTC			Complete if Known		
					Application Number	10/788,426	
				CLOSURE	Filing Date	March 1, 2004	
STATEMENT BY APPLICANT					First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
↸	Sheet 13 of 37		Attorney Docket Number	BAYER-0044			

		FOREIGN PA	TENT DOCU	MENIS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	C53	WO-98/52558	11-26-1998	Bayer Corporation et al.		
	C54	WO-98/52559	11-26-1998	Bayer Corporation et al.		
	C55	WO-98/52937	11-26-1998	G.D. Searle and Co et al.		
	C56	WO-98/52941	11-26-1998	G D. Searle and Co. et al.		
	C57	WO-98/56377	12-17-1998	SmithKline Beecham Corporation et al.		
	C58	WO-99/00357	01-07-1999	Vertex Pharmaceuticals Incorporated		
	C59	WO-99/00370	01-07-1999	Kurehs Kagaku Kogyo Kabushiki Kaisha		abs
	C60	WO-99/20617	04-29-1999	Pharmacia & UpJohn Company et al.		
	C61	WO-99/21835	05-06-1999	Fujisawa Pharmaceutical Co., Ltd. et al		
	C62	WO-99/23091	05-14-1999	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C63	WO-99/24035	05-20-1999	Bristol-Myers Squibb Company		
	C64	WO-99/24398	05-20-1999	Zeneca Limited et al.		
	C65	WO-99/24835	05-20-1999	Advanced Technology Materials, Inc.		
	C66	WO-99/26657	06-03-1999	Medical University of South Carolina et al.		
	C67	WO-99/28305	06-10-1999	E.I. Dupont De Nemours & Company et al.		
	C68	WO-99/32106	07-01-1999	Bayer Corporation		
	C69	WO-99/32109	07-01-1999	Bristol-Myers Squibb Company		
	C70	WO-99/32110	07-01-1999	Bayer Corporation	l	
	C71	WO-99/32111	07-01-1999	Bayer Corporation		

Examiner Date Considered Signature

EVEX.NDEC In Ideal of reference considered, whether or not dation is in conformance with MFEP 600. Draw line through citation if not in conformance and not considered include copy of the form with not communication to applicant. Applicant's unpeac citation designation number (colorisis) ¹/₂ See Medic Codes of USFTO Parent Documents as warrangs.latging or 16PF 010 of 16 father Office that inscured the colorisms by the host lines only MFOD Standards of 37. For spaces pages and education, the indication of the discoursed under the colorisms of the colorisms of

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

1	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
				CLOSURE	Filing Date	March 1, 2004	
	STATEMENT BY APPLICANT				First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
◟	Sheet	14	of	37	Attorney Docket Number	BAYER-0044	

Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ² - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т6
	C72	WO-99/32436	07-01-1999	Bayer Corporation		
	C73	WO-99/32437	07-01-1999	Slovako-Farma, A.S. et al.		
	C74	WO-99/32455	07-01-1999	Bayer Corporation		
	C75	WO-99/32463	07-01-1999	Bayer Corporation		
	C76	WO-99/33458	07-08-1999	Dalichi Pharmaceuticals Co., Ltd. et al.		abs
	C77	WO-99/35132	07-15-1999	Glaxo Group Limited et al.		
	C78	WO-99/40673	08-12-1999	Moving Magnet Technologies (S.A.) et al.		abs
	C79	WO-99/58502	11-18-1999	Vertex Pharmaceuticals Incorporated et al.		
	C80	WO-99/62890	12-09-1999	Pfizer Products inc. et al.		
	C81	WO-99/12497	03-09-2000	Scios Inc. et al.		
	C82	WO-00/17175	03-30-2000	Vertex Pharmaceuticals Incorporated et al		
	C83	WO-00/19205	04-06-2000	Advanced Research and Technology Institute, inc. et al.		
	C84	WO-00/26203	05-11-2000	Pharmacia & UpJohn S.P.A. et al.		
	C85	WO-00/27414	05-18-2000	BASF Aktiengesellschaft et al		
	C86	WO-00/31238	06-02-2000	Genetica, Inc. et al.		
	C87	WO-00/34303	08-15-2000	Isis Pharmaceuticals, Inc. et al.		
	C88	WO-00/35454	06-22-2000	Du Pont Pharmaceuticals Company		
	C89	WO-00/35455	06-22-2000	Telik. Inc.		
	C90	WO-00/39101	07-06-2000	Astra Zeneca UK Limited et al		
	C91	WO-00/39116	07-06-2000	Telkoku Hormone MFG. Co., Ltd.		abs

Date Considered Signature "EXAMINE! Index interesco considered, whether or not distinct in a conformance with MEPF 800. Draw has through called in it is conformated and not considered include copy of the torse with head commission to applical." Applicant unsign calculated copy of the protocopy of the first doctor of USF*0 P deter D coursets at assumptions page of MEPF 801.00. Either USF 800.00. Ei

WEO Standard S1. To F possible. "Applicant is to place a clock mank here it a right language interestable in attacked as 1. To F possible." Applicant is to place a clock mank here it a right language interestable interestable in the place whech is to the grant property and projection. Confidentially in application from the facility of the property and authority of the property of the property and authority of the property and authority of the property and authority of the property of the Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are requir to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO					Complete if Known		
	INFORMATION DISCLOSURE				Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	Y A	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
	(Use as many sheets as necessary)				Examiner Name	Heidi L. Reese	
$\overline{}$	Sheet	15	of	37	Attorney Docket Number	BAVER-0044	

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶				
	C92	WO-00/41698	07-20-2000	Bayer Corporation et al.						
	C93	WO-00/42012	07-20-2000	Bayer Corporation et al.						
	C94	WO-00/43366	07-27-2000	Kirin Beer Kabushiki Kaisha		abs				
	C95	WO-00/43384	07-27-2000	Boehringer Ingelheim Pharmaceuticals, Inc						
	C96	WO-00/47577	08-17-2000	SmithKline Beecham PLC et al						
	C97	WO-00/50425	08-31-2000	Boehringer Ingelherm Pharmaceuticals, Inc.						
	C98	WO-00/55139	09-21-2000	Boehringer Ingelheim Pharmaceuticals, Inc.						
	C99	WO-00/55152	09-21-2000	Boehringer Ingelheim Pharmaceuticals, Inc.						
	C100	WO-00/56331	09-28-2000	Vertex Pharmaceuticals Incorporated et al.						
	C101	WO-00/71506	11-30-2000	Telik, Inc.						
	C102	WO-00/71532	11-30-2000	Pfizer Products Inc. et al.						
	C103	WO-01/04115	01-18-2001	Boehringer Ingelheim Pharmaceuticals, Inc.						
	C104	WO-01/07411	02-01-2001	Banyu Pharmaceutical Co., Ltd.		abs				
	C105	WO-01/09088	02-08-2001	Krin Beer Kabushiki Kaisha et al.						
	C106	WO-01/12188	02-22-2001	Pharmacia & UpJohn S.P.A. et						

Considered Signature

Date

Examiner

Exclusive India 4 indexence considered, whether or not californ in a conformance with MEPF 600. Draw line in tough, dataset if not in conformance and not considered a management of the region of the proper management of the region of the region of the proper management of the region of the region of the proper management of the region of the Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

1	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	_
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STATEMENT BY APPLICANT				First Named Inventor	Jacques Dumas	
					Art Unit	1625	
	(Use as many sheets as necessary)				Examiner Name	Heidi L. Reese	
ľ	Sheet	16	of	37	Attorney Docket Number	BAYER-0044	

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶				
	C107	WO-01/36403	05-25-2001	Boehringer Ingelheim Pharmaceuticals, Inc. et al						
	C108	WO-01/47892	07-05-2001	American Home Products Corporation						
	C109	WO-01/54723	08-02-2001	Sunnybrook Health Science Center et al.						
	C110	WO-01/54727	08-02-2001	The Van Kampen Group, Inc. et al.						
	C111	WO-01/57008	08-09-2001	BASF Aktiengesellschaft et al.						
	C112	WO-01/63403	08-30-2001	Sun Microsystems, Inc						
	C113	WO-01/66099	09-13-2001	Astra Zeneca AB et al.						
	C114	WO-01/66540	09-13-2001	SmithKline Beecham P.L.C. et al.						
	C114a	WO-01/80843	11-01-2001	Supergen, Inc. et al						
	C115	WO-02/06382	01-24-2002	General Electric Company						
	C116	WO-02/07747	01-31-2002	Joslin Diabetes Center, Inc. et al.						
	C117	WO-02/07772	01-31-2002	Boehringer Ingelherm Pharmaceuticals, Inc.						
	C118	WO-02/10141	02-07-2002	Pfizer Products Inc. et al.						
	C119	WO-02/14281	02-21-2002	Cochran et al.						
	C120	WO-02/14311	02-21-2002	Amgen Inc. et al.						
	C121	WO-02/18346	03-07-2002	Pfizer Products Inc. et al.						
	C122	WO-02/24635	03-28-2002	Fujisawa Pharmaceutical Co , Ltd et al						
	C123	WO-02/25286	03-28-2002	The President and Fellows of Harvard College						
	C124	WO-02/32872	04-25-2002	Eisai Co., Ltd.		abs				
	C125	WO-02/40445	05-23-2002	Novo Nordisk A/S						
	C126	WO-02/42012	05-30-2002	Brill						

Examiner Date Signature Considered

EXAMINER, India if reference considered, whether or not datation is in conformance with MFPE 80D. Dave line through catalon if not in conformance and not considered include copy of this form with not of communication to applicant. Applicant's usage catalon designation number (optional). See Refine Coolean of USPTO Planet Documents are used to the communication of the Coolean of USPTO Planet Documents are used in the part of the Englanet Designation and the Coolean of USPTO Planet Documents are used in the option of the Englanet Documents are used in the option of the Englanet Documents are used in the Englanet Documents and the Englanet Documents are used to the Englanet Documents are used in the Englanet Documents are used to the Englanet D

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

1	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
				CLOSURE	Filing Date	March 1, 2004	
	STATEMENT BY APPLICANT				First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
┖	Sheet	17	of	37	Attorney Docket Number	BAYER-0044	

	1.7		Autoricy Doc		L11 00++	
		FOR	EIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵	Publication Date (M.known) MM-DD-YYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
	C127	WO-02/44156	06-06-2002	Limited et al.		
	C128	WO-02/44158	06-06-2002	Pfizer Products Inc. et al.		
	C129	WO-02/50091	06-27-2002	Glaxo Group Limited et al.		
	C130	WO-02/059081	08-01-2002			
	C131	WO-02/059102	08-01-2002	Aventis Pharma S.A. et al.		abs
	C132	WO-02/060900	08-08-2002	Telik, Inc. et al.		
	C133	WO-02/062763	08-15-2002	Bayer Corporation et al.		
	C134	WO-02/070008	09-12-2002	Imclone Systems Incorporated et al		
	C135	WO-02/076930	10-03-2002			
	C136	WO-02/076977	10-03-2002	Bayer Corporation et al.		
	C137	WO-02/083628	10-24-2002	Inc.		
	C138	WO-02/083642	10-24-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C139	WO-02/085857	10-31-2002	Bayer Corporation et al.		
	C140	WO-02/085859	10-31-2002	Bayer Corporation et al.		
	C141	WO-02/088090	11-07-2002	Incorporated et al.		
	C142	WO-02/092576	11-21-2002	Inc.		
	C143	WO-03/004523	01-16-2003	al.		
	C144	WO-03/005999	01-23-2003	Inc.		
	C145	WO-03/047523	06-12-2003	Inc.		
	C146	WO-03/047579	06-12-2003	Bayer Corporation et al.		

Examiner Date Signature Considered

This collection of information is equired by 30°CF1 (37 and 188. The information is required to obtain or information in the property in the property information in industrial or the information in the property information in industrial or the information in industrial information industrial industrial

Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1	Substitute	for form 1449A/PTC			Complete if Known						
					Application Number	10/788,426					
				CLOSURE	Filing Date	March 1, 2004					
	STATEMENT BY APPLICANT				First Named Inventor	Jacques Dumas					
					Art Unit	1625					
	(Use as many sheets as necessary)				Examiner Name	Heidi L. Reese					
Z	Sheet	18	of	37	Attorney Docket Number	BAYER-0044					
г	_										

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
	C147	WO-03/056036	07-10-2003	Catalyst Biomedica Limited et al.					
	C148	WO-03/059373	07-24-2003	Ramot at Tel Aviv University Ltd. et al					
	C149	WO-03/060111	07-24-2003	Catalyst Biomedica Limited et al.					
	C150	WO-03/065995	08-14-2003	Supergen, Inc. et al.					
	C151	WO-03/068223	08-21-2003	Bayer Corporation et al					
	C152	WO-03/068228	08-21-2003	Bayer Corporation et al.					
	C153	WO-03/068229	08-21-2003	Bayer Corporation et al					
	C154	WO-03/068746	08-21-2003	Bayer Corporation et al.		<u> </u>			
	C155	WO-03/082272	10-09-2003	Chiron Corporation et al					
	C156	WO-03/094626	11-20-2003	KMB Produktions AG et al.		abs			
	C156a	WO-03/097854	11-27-2003	Sugen, Inc. et al.					
	C157	WO 03/099771	12-04-2003	Novartis AG et al.					
	C158	WO-2004/004720	01-15-2004	Astex Technology Limited et al.					
	C159	WO-2004/019941	03-11-2004	MERCK PATENT GMBH et al					
	C160	WO-2004/037789	05-06-2004	MERCK PATENT GMBH et al.					
	C161	WO-2004/043374	05-27-2004	Dana-Farber Cancer institute Inc. et al.					
	C162	WO-2004/045578	06-03-2004	NOVARTIS AG et al					
	C163	WO-2004/052880	06-24-2004	ASTRAZENECA AB et al.					
	C164	WO-2004/078128	09-16-2004	Bayer Pharmaceuticals Corporation et al.					
	C165	WO-2004/078748	09-16-2004	Bayer Pharmaceuticals Corporation et al.					
	C166	WO-2004/078747	09-16-2004	Bayer Pharmaceuticals Corporation et al.					
	C167	WO-2004/078748	09-16-2004	Bayer Pharmaceuticals Compration et al.					

Signature Considered

Date

Examiner

EVAINABLE (Initial 3" reference considered, whether or not children is in conformance with METP 600. Draw line through children i' not in conformance and not considered with a conformance of the conforma Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are require ed to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTC)		Complete if Known		
				Application Number	10/788,426	
INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
STAT	EMENT B	Y A	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Sheet	Sheet 19 of 37		Attorney Docket Number	BAYER-0044		
			EODEICH D	ATENT DOCUMENTS		

Examiner Cite		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	Т
	C168	WO-2004/085399	10-07-2004	MERCK PATENT GMBH et al		
	C169	WO-2004/085425	10-07-2004	AMGEN INC.		
	C170	WO-2004/108713	12-16-2004	Warner-Lambert Company LLC et al.		
	C171	WO-2004/108715	12-16-2004	Warner-Lambert Company LLC et al.		
	C172	WO-2004/113274	12-29-2004	Bayer Pharmaceuticals Corporation et al.		
	C173	WO-2005/000284	01-06-2005	Bayer Pharmaceuticals Corporation et al.		
	C174	WO-2005/002673	01-13-2005	Astex Technology Limited et al.		
C175		WO-2005/004863	01-20-2005	GMBH et al.		
	C176	WO-2005/004864	01-20-2005	MERCK PATENT GMBH et al		
	C177	WO-2005/005389	01-20-2005	MERCK PATENT GMBH et al.		
C17	C178	WO-2005/005434	01-20-2005	NOVARTIS AG et al.		
	C179	WO-2005/009367	02-03-2005	AMBIT BIOSCIENCES CORPORATION et al.		
	C180	WO-2005/009961	02-03-2005	Bayer Pharmaceuticals Corporation et al.		
	C181	WO-2005/011700	02-10-2005	SMITHKLINE BEECHAM CORPORATION et al.		
	C182	WO-2005/018252	02-24-2005	Ariad Gene Therapeutics, Inc. et al.		
	C183	WO-2005/019192	03-03-2005	MERCK PATENT GMBH et al		abs
	C184	WO-2005/032548	04-14-2005	CHIRON CORPORATION et al.		
	C185	WO-2005/037273	04-28-2005	CHIRON CORPORATION et al.		
	C186	WO-2005/037285	04-28-2005	CHIRON CORPORATION et		

Considered Signature EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered

"EXAMINES! Initial if selevenes considend, whether or not dation is in conformance with MEPE DD Dark line through calcitor if not a conformance and not considered include cogol with one private with respect to the common of the conformation of the common Alexandria VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

Substitute	for form 1449A/PTC)		Complete if Known			
				Application Number	10/788,426		
INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004		
STAT	TEMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas		
				Art Unit	1625		
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese		
Sheet	20	of	37	Attorney Docket Number BAYER-0044			

FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T _e				
	C187	WO-2005/037829	04-28-2005	MERCK PATENT GMBH et al		abs				
	C188	WO-2005/042520	95-12-2005	MERCK PATENT GMBH et al.		abs				
	C189	WO-2005/047283	05-26-2005	MERCK PATENT GMBH et al.		abs				
	C190	WO-2005/048948	06-02-2005	Ambit Biosciences Corporation et al.						
	C191	WO-2005/049803	06-02-2005	MERCK PATENT GMBH et al.		abs				
	C191a	WO-2005/056764	08-23-2005	Compound Therapeutics, Inc. et al.						
	C192	WO-2005/058832	06-30-2005	MERCK PATENT GMBH et al						
	C192a	WO-2005/059179	06-30-2005	Bayer Pharmaceutical Corporation et al.						
	C193	WO-2005/075425	08-18-2005	MERCK PATENT GMBH et al.						
	C194	WO-2005/089443	09-29-2005	The Penn State Research Foundation et al.						
	C195	WO-2005/110994	11-24-2005	Bayer Pharmaceuticals Corporation et al.						
	C196	WO-2006/026500	03-09-2006	Bayer Pharmaceuticals Corporation et al.						
	C197	WO-2006/026501	03-09-2006	Bayer Pharmaceuticals Corporation et al.						
	C198	WO-2006/027346	03-16-2006	ALTANA PHARMA AG et al.						
	C199	WO-2008/034797	04-06-2006	BAYER HEALTHCARE AG et al.						
	C200	WO-2006/094626	09-14-2006	BAYER HEALTHCARE AG et al.						
	C201	WO-2006/105844	10-12-2006	MERCK PATENT GMBH et al		abs				
	C202	WO-2006/125540	11-30-2006	BAYER HEALTHCARE AG et al						
	C203	WO-2007/015947	02-08-2007	BAYER HEALTHCARE LLC et al.						
	C204	WO-2007/039403	04-12-2007	ALTANA PHARMA						

Considered

Signature

Exclusion Indigent and a finded and a second considered, whether or not define in a continuous with MEPS dots. Draw line in rough indigent in an in a continuous and not a considered with the continuous and indigent in the continuous and indigent indigent in the continuous and indigent in Alexandria, VA 22313-1450.

_		UI NOI 1 IO I APOI WU	IK I IBUU	AUTHA OF 1880, NO persons an	s required to respond to a corection or it	romanor driess i cortains a valid Divis cortio number					
(Substitute	for form 1449A/PTC)		Complete if Known						
					Application Number 10/788,426						
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004					
	STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas					
					Art Unit	1625					
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese					
$\overline{}$	Sheet	heet 21 of 37			Attorney Docket Number BAYER-0044						

Examiner	Oir.	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	Cite No. ¹	Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	C205	WO-2007/039404	04-12-2007	ALTANA PHARMA AG et al.		
	C205a	WO-2007/047955	04-26-2007	BAYER HEALTHCARE LLC et al.		
	C206	WO-2007/053573	05-10-2007	Bayer Pharmaceuticals Corporation et al.		
	C207	WO-2007/054215	05-18-2007	BAYER HEALTHCARE AG et al.		
	C207a	WO-2007/056011	05-18-2007	BAYER HEALTHCARE LLC et al.		
	C207b	WO-2007/056012	05-18-2007	BAYER HEALTHCARE LLC et al.		
	C208	WC 2007/059094	05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C209	WO-2007/059154	05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C210	WO-2007/059155	05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C211	WO-2007/084872	06-07-2007	Bayer Pharmaceuticals Corporation et al.		
	C215	WO-2007/123722	11-01-2007	Bayer Pharmaceuticals Corporation et al.		
	C216	WO-2007/139930	12-06-2007	Bayer Pharmaceuticals Corporation et al.		
	C218	WO-2008/079968	07-03-2008	Bayer Pharmaceuticals Corporation et al.		
	C219	WO-2008/079972	07-03-2008	Bayer Pharmaceuticals Corporation et al.		
	C220	WO-2008/089389	07-24-2008	Bayer Pharmaceuticals Corporation et al.		
	D1	EP-0016371	10-01-1980	F. Hoffman-La Roche & Co. Aktiengesellschaft		abs

Signature Considered

Exclusion in the process of the proc Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

-	_	OTABLE FIDE CAPOLING	III I IDUU	JOB TEX OF 1000, NO PORODE OF	o roquiros to rooparia to a conocitor o n	IOTTODO TOTODO IL CONTENDO A VANCIONIDI CONTO TIANDO			
(Substitute	for form 1449A/PTC)		Complete if Known				
					Application Number	10/788,426			
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004			
	STAT	TEMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas			
					Art Unit	1625			
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese			
Z	Sheet	22	of	37	Attorney Docket Number	BAYER-0044			

		FOREIGN PA	TENT	DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁶ (if known)		lication Date D-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	D2	EP-0107214	05-02-1984 Duphar International Research B.V.		International		
	D3	EP-0116932	08-2	9-1984	BASF Aktiengesellschaft		abs
	D3a	EP-0192263	07-2	9-1992	Ishihara Sangyo Kaisha Ltd. et al.		
	D4	EP-0192263		7-1986	Ishihara Sangyo Kaisha Ltd. et al.		
	D5	EP-0202538	11-2	6-1986	Bayer AG		abs
	D6	EP-0230400	07-2	9-1987	CIBA-GEIGY AG		abs
	D6a	EP-0233559	08-2	6-1987	Ishihara Sangyo Kaisha Ltd. et al.		
	D7	EP-0233559	05-0	6-1992	Ishihara Sangyo Kaisha Ltd. et al.		
	D8	EP-0242666		8-1987	BASF Aktiengesellschaft		abs
	D9	EP-0264904	04-2	7-1988	Ishihara Sangyo Kaisha Ltd. et al.		
	D10	EP-0314615		3-1989	Ciba-Geigy AG		abs
	D11	EP-0335156	10-0	4-1989	Bayer AG		abs
	D12	EP-0359148		1-1990	Ishihara Sangyo Kaisha, Ltd. et al.		
	D13	EP-0371876		6-1990	Novapharme		abs
	D14	EP-0379915	08-0	1-1990	Bayer AG		abs
	D15	EP-0380048	08-0	1-1990	Ishihara Sangyo Kaisha Ltd		
	D16	EP-0381987	08-1	6-1990	Ishihara Sangyo Kaisha, Ltd. et al.		
	D17	EP-0405233	01-0	2-1991	Mitsubishi Kasei Corporation		
	D18	EP-0425443	05-0	2-1991	Ciba-Geigy AG		abs
	D19	EP-0459887	12-0	4-1991	Novapharme		abs
	D20	EP-0502504	09-0	9-1992	Matsushita Electric Industrial Co., Ltd.		
	D21	EP-0509795	10-2	1-1992	American Home Products Corporation		
	D22	EP-0676395	10-1	1-1995	Hoechst Aktiengesellschaft		abs
	D23	EP-0690344	01-0	3-1996	Konica Corporation		
	D24	EP-0709220	05-0	1-1996	Canon Kabushiki Kasha		
Examiner Signature				Date Consid	ered		

EXAMINER Inhal if reference considered, whether or not diation is in conformance with MFPE 900 Draw line through citation if not in conformance and not considered include copy of the form with not communication to applicant. Applicant is usual existence designation number (potional). See Medic Cocke of USFO Patent Documents are view of the regin of the Expensive Interval of the Interval of the Interval of Inter

		Ulidei sie i apervo	IK I IDUU	COULT PLC OF 1880, TO PORSONIO OF	s required to respond to a conscriot of it	IOTHADOTO 1688 ILCOHATIS A VAIG CIVID CONTO HUTTOS			
1	Substitute	for form 1449A/PTC)		Complete if Known				
					Application Number	10/788,426			
				CLOSURE	Filing Date	March 1, 2004			
STATEMENT BY APPLICANT					First Named Inventor	Jacques Dumas			
					Art Unit	1625			
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese			
V	Sheet	23	of	37	Attorney Docket Number	BAYER-0044			

			FOREIGN P	ATENT DOCU	IMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent	Document Number ⁴ - Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	D24s		EP-0709225	05-01-1996	Nippon Paper Industries Co., Ltd.		
	D25		EP-0709225	08-05-1998	Nippon Paper Industries Co., Ltd.		
	D26		EP-0860433	08-26-1998	Kırın Beer Kabushiki Kaisna		
	D27		EP-1056725	12-06-2000	Bayer Corporation		
	D28		EP-1199306	04-24-2002	Banyu Pharmaceutical Co., Ltd		
	D29		EP-1256587	11-13-2002	The Kitasato Institute		
	D30		EP-1537075	06-08-2005	Neurosearch A/S et al.		
	E1		CH-479557	11-28-1969	Dr. A Wander AG		abs
F1			CL-38688	06-04-1993	Ciba-Geigy AG		
	G1		CA-2 146 707	10-12-1995	Hoechst Aktiengesellschaft		
	G2	GA-2,028.536		04-28-1991	Ciba-Geigy AG		
	H1		DD-253997	02-10-1988	Karl-Marx- Universität, Büro Für Neuerungen und Schutzrechte		abs
	н		DE-487014	11-14-1929	I.G. Farbenindustrie Akt -Ges		
	12		DE-511468	10-16-1930	I.G. Farbenindustrie Akt -Ges		abs
	13		DE-523437	04-02-1931	I.G Farbenindustrie Akt -Ges		
	14		DE-2436179	04-10-1986	Shionogi & Co. Ltd.		abs
	15		DT-2501648	07-24-1975	The Dow Chemical Co		abs
	16		DT-2436179	02-06-1975	Shionogi & Co., Ltd.		abs
	17		DE-3305866	08-23-1984	BASF AG		abs
	18		DE-3529247	11-20-1986	Bayer AG		abs
	19		DE-3540377	05-21-1987	Bayer AG		abs
	J1 FR-1.		FR-1.457.172	09-19-1966	Ferrania S.p.A.		abs
	K1	GB-771,333		03-27-1957	J R. Geigy AG.		
	K2		GB-828,231	02-17-1960	J.R. Geigy AG.		

Signature Considered EXAMENT initial if reference considered, whether or not citation is in conformance with MEEP 600 Draw line through citation if not in conformance and not considered include copy of the form with rest communication to applicant. *Applicant's using a citation designation number (optional)* See finds Code of USPTO Patent Documents of the communication to applicant. *Applicant's using a citation designation number (optional)* See finds Code of USPTO Patent Documents of use of the region to the Engineer International Communication and Code of USPTO Patent Documents of use of the region to the Engineer International Code of USPTO Patent Documents of USPTO Patent Doc

This Collection of information is equipped by 30 most by 80 cm and 30 most of the second of ordinary benefits of the pulse within a finite facility of the pulse within a finite facilit

		Under the Paperwo	rk Hedu	ction Act of 1995, no persons an	e required to respond to a collection of in	nformation unless if contains a valid OMB control number		
1	Substitute	for form 1449A/PTC)		Complete if Known			
ı					Application Number	10/788,426		
ı	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004		
ı	STAT	TEMENT B	ΥΑ	PPLICANT	First Named Inventor	Jacques Dumas		
ı					Art Unit	1625		
L		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese		
Z	Sheet	neet 24 of 37		Attorney Docket Number	BAYER-0044			

_	1-1	51 51			LIT OUTT	
			ATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
	K3	GB-921,682	03-20-1963	J.R. Geigy AG.		
	K4	GB-1,110,099	04-18-1968	Rhone- Poulenc S.A.		
	K4a	GB-1 111,554	05-01-1968	Societa Per Azioni Ferrania		
	K5	GB-1 590 870	06-10-1981	Shlonogi Seiyaku Kabushiki Kaisha.		
	L1	HU-P0004437	08-28-2001	Bayer Corporation		abs
	M1	IR-26555	01-13-2000	Bayer Corporation		abs
	N1	JP-44-2569	02-03-1969	Sankyo Co., Ltd. and Asahi Chem. Ind. Co., Ltd		abs
	N2	JP-50-76072	06-21-1975	Shionogi Selyaku KK		abs
	N3	JP-50-77375	06-24-1975	Shionogi Seiyaku KK		abs
	N4	JP-50-149668	11-29-1975	unknown		abs
	N5	JP-51-63170	06-01-1976	Shionogi Shinzaburo		abs
	N6	JP-61-80862	07-15-1976	Shionogi Seiyaku KK		abs
	N7	JP-53-86033	07-29-1978	Shionogi Co Ltd.		abs
	N8	JP-54-32468	09-03-1979	Otsuka Pharmaceutical Co Ltd.		abs
	N9	JP-55-98152	07-25-1980	HOKKO CHEM. IND. CO		abs
	N10	JP-55-124763	09-26-1980	Ishihara Mining & Chemical Co.		abs
	N11	JP-55-162772	12-18-1980	Shionogi & Co. Ltd.		abs
	N13	JP-57-53785	11-15-1982	Shionogi Selyaku KK		abs
	N14	JP-58-21626	05-02-1983	Shlonogi Selyaku KK		abs
	N16	JP-61-20039	01-28-1986	Konishiroku Photo Ind. Co., Ltd.		abs
	N15	JP-63-214752	09-07-1988	Fuji Photo Film Co. Ltd.		abs
	N17	JP-64-9455	01-12-1989	Fuji Photo Film Co., Ltd.		abs
	N18	JP-1-102461	04-20-1989	Konica Corp.		abs
	N19	JP-1-132580	05-25-1989	Ciba Geigy AG		abs
	N20	JP-1-200254	08-11-1989	Konica Corp.		abs

Signature Considered

EXAMAGE Initial I reference considered, whether or not distinon is in conference with MEPE 600 Date like high capital for the conference with MEPE 600 Date like high capital for the conference with MEPE 600 Date like high capital for long pictured. Applicant is unappeared by the long of the form with next communication to applicant. Applicant is unappeared by the long the conference of the picture of the pic

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	Substitute for form 1449A/PTO				Complete if Known					
					Application Nur	nber	10/78	88,426		
INFO	ORMA'	TION	DIS	CLOSURE	Filing Date		Marc	h 1, 2004		
STA	STATEMENT BY APPLICANT					ventor	Jacqu	ues Dumas		
					Art Unit		1625	1625		
	(Use as many sheets as necessary)					Examiner Name		Heidi L. Reese		
Sheet	25		of	37	Attorney Docket Number BAYER-0044			ER-0044		
				FOREIGN PA	ATENT DOCU	MENTS				
Examiner	Cite	Foreign F	atent	Document	Publication	Name of Pate	itee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.1	Country Code ² - Number ⁴ - Kind Code ⁵ (if known)		Date MM-DD-YYYY	Applicant of Cited Document		Passages or Relevant Figures Appear	T ⁶		
	N21	JP-1-259360			10-17-1989	Konica Corp.			abs	

Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Where Relevant	i	
Initials*	No.1	Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶	
	N21	JP-1-259360	10-17-1989	Kenica Corp.		abs	
	N22	JP-2-22650	01-25-1990	Konica Corp.		abs	
	N23	JP-2-23337	01-25-1990	Konica Corp.		abs	
	N24	JP-2-35450	02-06-1990	Konica Corp.		abs	
	N25	JP-2-105146	04-17-1990	Konica Corp.		abs	
	N26	JP-2-108048	04-19-1990	Konica Corp.		abs	
	N27	JP-2:150840	06-11-1990	Konica Corp.		abs	
	N28	JP-3-53247	03-07-1991	Fuji Photo Film Co Ltd.		abs	
	N29	JP-3-144634	06-20-1991	Konica Corp.		abs	
	N30	JP-3-198049	08-29-1991	Fuji Photo Film Co. Ltd.		abs	
	N31	JP-6-75172	09-21-1994	Fuji Photo Film Co. Ltd.		abs	
	N32	JP-8-301841	11-19-1996	Green Cross Corp. et al.		abs	
	N33	JP-10-306078	11-17-1998	Mitsubishi Chemical Corp.		abs	
	01	LB-6124	01-12-2000	Bayer Corporation.			
	T-F1	CL-38688	06-04-1993	Ciba-Geigy AG			
	T-11	DE-487014	11-14-1929	I.G. Farbenindustrie AktGes.			
	T-I3	DE-523437	04-02-1931	I.G. Farbenindustrie			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2						
	P7	Avruch et al., "Raf meets Ras. completing the framework of a signal transduction pathway," TIBS 19; July 1994, pp. 279-263							
	P9a	Baka et al., "A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis," Expert Opinion Therapeutic Targets, 2006, Vol. 10, No.6, pp. 967-876							
	P10	Balam et al., "Metabolic Considerations in Prodrug Design," Chapter Twenty-Three In: Burger's Medicinal Chemistry and Drug Discovery, 5 th ed. John Wiley & Sons, Inc., New York, 1995: Vol. 1,pp. 949-982							
	P17	Berge et al. "Pharmaceutical Salts." Journal of Pharmaceutical Sciences. January 1977:1-19. Vol. 66, No. 1							

Examiner Date Considered Signature

Signature

Considered

EXAMINER Initial interence considered, whether or not dation is in conformance with MEP 600 Draw like through dation if not in conformance and not considered include copy of this form with near communication to applicant. Applicant's unspeciation designation number (optional) *See Redis Codes of USFD P letter Documents a way again, and the PEP 600 of *Electr Defends in tissued the document, by the host letter code (MPD) Standard 53 *1", for Lapenese plated document, in frequent to the pasted state of the pasted document. However, the pasted in the pasted state of the pasted document by the pasted pasted in the pasted document in the pasted document. However, the pasted pasted in the pasted document is pasted as the pasted pasted in the pasted document. However, the pasted pasted in the pasted document is pasted as the pasted pasted pasted in the pasted document is pasted paste Alexandria, VA 22313-1450.

Approved for use through 11/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/788 426 INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT First Named Inventor Jacques Dumas 1625 (Use as many sheets as necessary) Examiner Name Heidi L. Reese Sheet of 37 Attorney Docket Number BAYER-0044

Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	1					
No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
P22	Martin-Blanco "p38 MAPK signalling cascades, ancient roles and new functions," BioEssays, 22:637-845, 2000						
P23	Foussard-Blanpin, Odette, "Comparative pharmacological study of substituted carboxamides upon central nervous system," Ann. Pharm. Fr. (1982), 40 (4), pp. 339-350						
P25	Bollag et al., "Raf pathway inhibitors in oncology," Current Opinion in Investigational Drugs (2003) 4(12), pp. 1436-1441.						
P26	Botton et al., "Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherspy," Annual Reports In Medicinal Chemistry, Vol. 29. 1994, pp. 165-174						
P28a	Boyer, S.J., "Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activity Relationships," Current Topics in Medicinal Chemistry, 2002, Vol. 2, pp. 973-1000						
P50	Copéret et al., 'A Simple And Efficient Method for the Preparation of Pyridine-Woxides II," Tetrahedron Letters Elsevier Science Ltd., Pergamon Press, Oxford, UK 1998; Vol. 39, pp. 761-764						
P53a	Crump, Micheal, "Inhibition of raf kinase in the treatment of acute myeloid leukemia," Medline Abstract ISSN:1381-8128, Current Pharmaceutical Design, Vol. 8, Issue 25, 2002, pp. 2243-2248						
P57	Daum et al "The ins and cuts of Raf kinases," TIBS 19, November 1994, pp. 474-490						
P66	Dumas, J. "Protein kinase inhibitors from the urea class," Curr. Opin. in Drug Discovery and Dev., 5(s):718-727, 2002						
P67	Dumas et al., "Discovery of a New Class of p38 Kinase inhibitors," Bioorganic & Medicinal Chemistry Letters Vol. 10, (2000), pp. 2047-2050						
P68	Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors," Bioorganic & Medicinal Chemistry Letters, 2000, Vol. 10, pp. 2051-2054						
P68a	Dumas, J., "Growth factor receptor kinase inhibitors: Recent progress and clinical impact," Current Opinion in Drug Discovery & Development, 2001, Vol. 4, No. 4, pp. 378-389						
P68b	Dumas, J., "Protein kinase inhibitors: emerging pharmacophores 1997-2000," Expert Opinion on Therapeutic Patents (2001) Vol. 11, No. 3, pp. 405-429						
P68c	Dumas et al., "Orally Active p38 Kinase Inhibitors from the Urea Class," Poster, 222nd American Cancer Society National Meeting 2001, Med 1256, 1 page						
P68d	Dumas, J., 'Raf Kinase Inhibitors,' Expert Opinion on Therapeutic Patients. Vol. 8, No. 12, pp. 1749-1750, 1998						
P69	Dumas et al., "Recent developments in the discovery of protein kinase inhibitors from the urea class," Current Opinion in Drug Discovery & Development, 2004, Vol. 7, Number 5, pp. 600-616						
	P23 P25 P26 P28a P50 P53a P57 P66 P67 P68 P68a P68a	P23 Fousaard Blanon, Odette, 'Comparative pharmacological study of substituted carboxamides upon central nervous system,' Ann Pharm. Fr. (1982), 40 (4), pp. 339-350. P25 Bollag et al., 'Tal pathway inhibitors in oncology,' Current Opinion in Investigational Drugs (2003) 4(12), pp. 1439-1441. P26 Bollag et al., 'Tal pathway inhibitors in oncology,' Current Opinion in Investigational Drugs (2003) 4(12), pp. 1439-1441. P26 Botten et al., 'Talse Choopean Directed Approaches in Canzer Chemotherapy,' Annual Reports in Medional Chemistry, Vol. 29, 1954-3, pp. 156-174 P28 Boyer, S.J., 'Small Mideoule Inhibitors of KDR (WEGFR-2) Kinase: An Overview of Structure Activity Pelastioniships.' Current Topics in Medicinal Chemistry, 2002, Vol. 2, pp. 973-100. P29 Boyer, S.J., 'Small Mideoule Inhibitors of KDR (WEGFR-2) Kinase: An Overview of Structure Activity Pelastioniships.' Current Topics in Medicinal Chemistry, 2002, Vol. 2, pp. 973-100. P29 Copiert et al., 'A Simple And Efficient Method for the Preparation of Pyridine-Anoxides II,' Tetrahedron Leners Elevere Science Ltd., 'Pergamon Press, Colord, IX 1983- Vol. 30, pp. 781-794 P29 Curren, Michael, 'Thiobition of ral Minase in the treatment of acute myeloid leukemar.' Medine Abstract ISSN 1381-9128, Current Pharmacoedical Besign, Vol. 8, Issue 25, 2002, pp. 2243-2248 P29 Current al., 'The instance and cuts of Ral Kinases,' TIBS 19, November 1994, pp. 474-499 Dumas et al., 'Thiopics and cuts of Ral Kinases,' TIBS 19, November 1994, pp. 474-499 Dumas et al., 'Thiopy-5-pyrazoly (Unear: Potent and Selective p39 Kinases Inhibitors,' Bioorganio & Medicinal Chemistry Lotters Vol. 10, (2000), pp. 2047-2050 Dumas et al., 'Thiopy-5-pyrazoly (Unear: Potent and Selective p39 Kinases Inhibitors,' Bioorganio & Medicinal Chemistry Lotters Vol. 10, (2000), pp. 2047-2050 Dumas et al., 'Thiopy-5-pyrazoly (Unear: Potent and Selective p39 Kinases Inhibitors,' Bioorganio & Medicinal Chemistry Lotters Patents (2011) Vol. 11, No. 3, pp. 405-429 Dumas et al., 'Thiopy-5-pyrazoly (Unea					

Signature		Considered	
	if reference considered, whether or not citation is in conformance		
	s form with next communication to applicant. Applicant's unique cita		
www.spto.gov.or	MPEP 901.04. Enter Office that issued the document, by the two-let	ter code (WIPO Standa	rd ST 3). For Japanese patent documents, the indication of the

www.scalago.go v MPEP 801.04 "Enter Office that issued the document, by the low-letter code (WIPO Standard ST 3)" For Japanese patert documents in the indication of the use of the reign of the Firegron trust proceeds be senal number of the planet document. When disposance is the Engine Interpretation is attached as a midcast do not held the wild because the wear of the process of the Engine Interpretation is attached to the Engine Interpretation in attached to the Engine Interpretation is attached to the Engine Interpretation in the Collection of Interpretation is required by 20°CH 197 and 181 for the Interpretation is required by 20°CH 197 and 181 for the Interpretation is required by 20°CH 197 and 181 for the Interpretation is required by 20°CH 197 and 181 for the Interpretation is required by 20°CH 197 and 181 for the Interpretation is required by 20°CH 197 and 181 for the Interpretation is required by 20°CH 197 and 181 for the Interpretation is required by 20°CH 197 and 181 for the Interpretation is required by 20°CH 197 and 20°CH 1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Sheet	27		of	37		Attorney Docket Number	BAYER-0044			
					NON PATENT	LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1			ook, ma	gazine, journal, s	TAL LETTERS), title of the arti erial, symposium, catalog, etc. sher, city and/or country where		T ²		
	P22	Martin 2000	-Blanco	, 'p38 M	APK signalling cas	cades: ancient roles and new functi	ons," BioEssays, 22.637-645,			
	P70		umas et al "Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor." oorganic & Medicinal Chemistry Letters, 2002, Vol. 12, pp. 1559-1562							
	P107		Gura, "Systems for identifying new drugs are often faulty," Solence, 1997, Vol. 276, (5840), pp. 1041-1042, WEDLINE with Full text VeiDLINE with Full text Choose of al., "Systemis and structure-activity relationship of quinazoline-urea derivatives as novel orally active VEDF reospot hyposne kinase selective inhibitors." Proceedings of the American Association of Cancer Res. 2002, Vol. 43, p. 10, 24 acteratine, 1911. Kurnar et al., "Drugs targefed against protein kinases" Expert Opin. Emerging Drugs 6(2):303-315 (2001)							
	P147	VEGF								
	P149	Kumar								
	P166	Lyons	Lyons et al., "Discovery of a novel Raf kinase inhibitor," Endocrine-Related Cancer, 2001, Vol. 8, pp. 219-225							
	P224	Regan et al., "Pyrazole Urea-Based Inhibition of p38 MAP kinase: From Lead Compound to Clinical Candidate," J. Med. Clem. 45:2984-0986, 2002 Smith et al., "Discovery of Heterocyclic Ureas as a New Class of Ral Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry Approach; "Boorganic & Medicinal Chemistry Letters, 2001, Vol. 11; "Bu. 277-277." Smith et al., (Abstract) Recent Advances in the Research and Development of RAF Kinase Inhibitors," Current Topics in Medicinal Chemistry 6(11):1071-1098 (2006)								
	P248									
	P249									
	P276 Thaimattam et al., "3D-QSAR CoMFA. CoMSIA studies on substituted ureas as Rai-1 kinase inhibitors and its confirmation with attuctuse-based studies," <i>Biocopanic & Mediciniar Chemistry</i> , 2004, Vol. 12, pp. 8415-8425 P278 Thompson et al., "Recorat progress in targeting the RaiMEK/ERR pathway with inhibitors in cancer drug discovery," Curr. Opin Pharmacol. August 2005. Vol. 8, Number 4, pp. 363-365									
	P294				ctural basis for the 1997. Vol. 4, Number	specificity of pyridinylimidazole inher er 6, pp. 423-431.	bitors of p38 MAP kinase,"			
	P312	Kubo et al., "Synthesis and Structure-Activity Relationship of Quinazohine-Urea Derivatives as Novel Orally Active VEGF Receptor Tyrosine Kinase Selective Inhibitors," Proceedings of the American Association of Cancer Res. 2002. Vol. 43, p. 182, abstract no. 913								
	P313	Procee	edings o	of the Arr	erican Association	nibitors from the Diphenyturea Clas for Cancer Research, Vol. 42, Man sociation for Cancer Research: Nev	ch 2001 (2001-03), page 923,			
	P315	Abstra	ct of Di	330586	36 A1, August 23, 1	984, BASF AG et al				

Signature Considered

Consider

Date

Examiner

WPO Standard ST 16 (possible "Applicant is to place a check mark here it English language Transition is attached." This collection of information is required by 20 TST 193 and 139. The information is required by the public which is to file (and by the USPTO to process) an application. Confidentially appeared by US IS 12 22 and 25 FST 14. The collection is estimated to take 2 hours to complete, entitleding gathering, preparing and scanning the confidentially applicant to the USPTO Time will vary depending upon the andeblast cases by comments on the most of time you cannot be completed application from to the USPTO Time will vary depending upon the andeblast cases by comments on the uncert of time you surprise to complete and scanning the complete application from the USPTO Time will vary depending upon the andeblastic seal, you comments on the uncert of the work of the complete and scanning the and scanning the complete and scanning the comp

Under the Paperwork Beduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

-		O ROO S TO T OPOS THO	1111000	COOL TEX CT 1000; TO POTOGED CO	o roquiros to rocporta to a conocitor o	Normalia a rando madria de a randi a r
1	Substitute	for form 1449A/PTC)			Complete if Known
					Application Number	10/788,426
				CLOSURE	Filing Date	March 1, 2004
	STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas
					Art Unit	1625
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese
$\overline{}$	Sheet	28	of	37	Attorney Docket Number	BAYER-0044

Onco.	20	Si Si Milonoy Booter Hamber British
		NON PATENT LITERATURE DOCUMENTS
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.
	P316	Abstract of EP 4931 A (Equivalent 4,240,820), Bayer AG, 1 page
	P317	Abstract of EP 16371 (1930), 1 page, Hottmann-La Roche AG
	P318	Abstract of EP 16371, October 1, 1980, 1 page
	P319	Abstract of EP 116932, August 29, 1984, 2 pages.
	P320	Abstract of EP 116932, (1984), 2 pages, BASF AG
	P321	Abstract of EP 0202538, (1986), 3 pages
	P322	Abstract of EP 0202538 A1, "Growth Promoting Agents, November 26, 1986, 4 pages, Bayer AG
	P323	Abstract of EP 0405233A1. Mitsubishi Kasei Corp., 2 pages
	P324	Abstract of EP 0405233A1, Tetsuo Sekiya et al., 1 page
	P325	Abstract of EP 0676395A2, (1995), 3 pages, Hoschst AG
	P326	Abstract of EP 676395, (U.S. equivalent 5,698,581). December 16, 1997. 1 page
	P327	Patent Abstracts of Japan 02-022650, 01-25-1990, 2 pages, Konica Corp
	P328	esp@cenet Abstracts of Japan 02-922850, 01-25-1990, 1 page
	P329	Patent Abstracts of Japan 02-023337, 01-25-1990 2 pages Konica Corp
	P329a	Patent Abstracts of Japan 63-214752, 09-07-1988, 2 pages, tamily member of JP 6-07512 B4, Fuji Photo Film Co. Ltd.
Examiner		Date

Date Considered Signature

EXPIDITION OF THE PROPERTY OF Alexandria, VA 22313-1450.

	Ulkibi sib i aporwo	IN I IDUU	JOHN ALC OF 1880, HU DEFROORS OF	s required to respond to a conscitor to	mornation driess it contains a valid Civib control full be	
Substitute	for form 1449A/PTC)		Complete if Known		
				Application Number	10/788,426	
INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
STAT	TEMENT B	Y A	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Shoot	20	of	37	Atterney Deaket Mumber	BAVED 0044	

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Т2 Cite Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials * number(s), publisher, city and/or country where published P330 esp@cenet Abstract of Japan 02-023337, 1 page Abstract of JP 55162772 A2. Preparation of Substituted Acetic Acid Derivatives, Shrongi & Co., Ltd. December D331 1980, 1 page P332 Esp@cenet Abstract of WO 9822103, 28 May 1998, Philip Hedge et al. P3328 Abstract of WO 9822098 A2, QLT Phototherapeutics Inc. et al., 05-28-1998, 1 page P333a Abstract of WO 9822103 A1, Zeneca Limited, published 05-28-1998, 1 page P333b Abstract of WO 9852559 A1, Bayer Corp. et al., published 11-26-1998, 1 page P333c Abstract of WO 9852562 A1, Verkaik, MSE, et al., published 11-26-1998, 1 page P333d Abstract of WO 9900357 A1, Vertex Pharm, Inc., published 01-07-1999, 1 page P333e Abstract of WO 9900364 A1, Pharmacia & Upjohn S.P.A. et al., published 01-07-1999, 1 page P333f Abstract of WO 9932098 A2, Janssen Pharm NV, published 07-01-1999, 1 page P333g Abstract of WO 9932106 A1, Bayer Corp., published 07-01-1999, 1 page P333h Abstract of WO 9932148 A1. Beth Israel Deaconess Medical Center et al., pub. 07-01-1999, 1 page P333i Abstract of WO 9932436 A1, Bayer Corp., published 07-01-1999, 1 page D2221 Abstract of MC 00224EE At. Payer Corp. published 07-01-1000, 1 page

	roooj	ALMERICO DE WO 8802400 AT. Dayle: Corp., publishe	ii 07-01-1000, 1 pag	o l	
Examiner Signature		A	Date Considered		

"ACCURATE TIME I retereze considend, whether or not delice in a notion more with NETE 500 their line through ciden it not a continuous and of considered holders or yet the September of the process of the continuous and of considered holders or yet the September of september of

WPO Standard ST 16 if possible in a potential to place a check mark have a finishing language. Translation in attached.

This catelation of information is required by 37 CPR 1 97 and 1 98. The information is required to obtain or between the benefit by the public which is to file (and by the USPTO to process) an application Confederability agreemed by 38 CPR 1 97 and 1 98. This catelant is 1 to the control of the process and t and aubmitting the completed application form to the USPTO Time will vary depending upon the andividual case. Any comments on the amount of time you equite to complete this form and/or suggestion for reducing the burden, should be sent to the Chief Information Officer, US Patient and Tasker to Set 100 to 100 Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

	_	Oradi sio i aparilo	1111100001	courrect or 1000, no porcorb a	o roquirou so rooparia so a conocitori on	TIOTHEROTE HOSE IT OUT IN THE TOTAL OF ITS CONTROL TO THE	
	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
				CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Ū	Sheet	30	of	37	Attorney Docket Number	BAYER-0044	

		,	
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	P333k	Abstract of WO 9932457 A1, Hoechst Marion Roussel Deutschland GmbH et al. published 07-01-1999, 1 page	
	P334	Caplus 72:79045, Abstract of CH 479557. "Tuberculostatic and cancerostatic polybasic ureas." Dr. A. Wander, October 15, 1969, 6 pages	
	P335	Caplus 84:180049, Abstract JP 58029871, "Substituted acetic acid derivatives," Hamada, Yoshinori et al., July 10, 1981, 1 page	
	P336	Caplus 84.43857, Abstract JP 58021626, "Alkanoic acid derivatives containing a pyridine ring," Maeda, Ryozo et al., May 2, 1983, 1 page	
	P337	Caplus 86:72448, Abstract JP 57053785, "Pyridine derivatives," Maeda. Hyozo et al., November 15, 1982, 1 page	
	P339	Caplus 98:78152, Abstract of JP 57185219, 'Antitumor benzophenone derivatives." November 15, 1982, 1 page, Chugai Pharmaceutical Co., Ltd.	
	P340	Caplus 113.108314, Abstract of JP 2022850, "Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove lecuo cyan dye," Noboru Mizukura et al. January 25, 1990, 1 page	
	P341	Caplus 113-142130, Abstract of JP 2023337, "Silver hallde photographic material containing phenolic cyan coupler a colorless cyan coupler," Toshihiko Yagi et al., January 25, 1990, 1 page	
	P346	Caplus 127.24137I, "Preparation of quinoline and quinazoline derivatives inhibiting plateier-derived growth factor receptor autophosphorylation," Kazuo Kubo et al., May 15, 1997, WO 97/17329	
	P347	Caplus 131'58658k, "Inhibition of rat kinase using symmetrical and unsymmetrical substituted diphenyl ureas," Miller, Scott, et al. July 1, 1999, WO 99 32,436	
	P348	Caplus 131.73849b, "Preparation of pyrazolyl aryl ureas and related compounds as p38 kinase inhibitors," Jacques Dumas et al., July 1, 1999, WO 99/32110	
	P352	"Beilstern number" Collection, 28 pp. (1997)	
	P353	*Beilstein number* Collection, 4 pp. (1997)	
	P354	Derwent World Patents Index Search pp 20-26. (1997)	
	P355	Dumas, J. "CAS Substructure," May 6, 1997, pp. 1-29	

Examiner Signature		Date Considered	

EXAMINE: Table 1 reference considered, whether or not delition in a noteromous will MEPS 000. There has though validate 7 for it is not removed and not considered in the control of the c Alexandria, VA 22313-1450.

-		Under the Laberton	IK I IBUU	COULT ACCUST 1880, TO PORSONIO OF	required to respond to a conscitor to	FIRST HAIROT OF 1888 IT CONTAINS A VARIO CIVID CONTROL TO THE TIDE	
	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
				CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	ΥΑ	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
ν-	Sheet 31 of 37			37	Attorney Docket Number	BAVER-0044	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials * No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	P356	Scott, Ball, 'Substructure (Patent Families),' August 11, 1997, pp. 1-19					
	P357	Scott, Bill, "Substructure #2," November 25, 1997, pp. 1-3					
	P358	Scott, Bill, "Substructure Search," December 2, 1997, pp. 1-49					
	P359	Substructure Search, pp. 1-29. (1997)					
	P360	Wild, Hanno, "Substructure #1," search, pp. 1-150, 1996					
	P361	A "Notice of References Cited" from the USPTO for U.S. application 08/995,749, filling date of 12/22/97, Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas, 2 pages					
	P362	A "Notice of References Cited" from the USPTO for U.S. application 09/083,399, filling date of 5/22/98, Patent 6187799 issued 2/13/2001, Inhibition of Raf Kinase Activity Using Aryl Ureas: 1 page					
	P363	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228, filling date of 10/22/99, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 3 pages					
	P364	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229, filling date of 10/22/99, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, 1 page					
	P365	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015, filling date of 12/10/1999 Inhibition Of p38 Kinase Using Symmetrical And Unsymmetrical Diphenyl Ureas, 1 page					
	P366	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filling date of 12/27/99, Patent 7329670 issued 2/12/2008, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas.					
	P367	A "Notice of References Cited" from the USPTO for U.S. application 09/472.232. filling date of 12/27/99, Patent 7329670 issued 2/12/2008, Imhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page.					
	P368	A "Notice of References Cited" from the USPTO for U.S. application 09/773,604 filling date of 2/2/01, Publication No. US 2001-0034447-A1, Publication Date 10/25/01, Omega-carboxyaryl Substituted Diphenyl Ureas as Ral Kinase inhibitors. 1 page.					
	P369	A "Notice of References Cited" from the USPTO for U.S. application 09/773,656, filing date of 2/2/01, Publication No.: US 2001-0011135 A1. Publication Date: August 2, 2001, Omega-carboxyaryl Substituted Dipherel Uresa & Ra fix Kinse einhibitors, 1 page					
	P370	A "Notice of References Cited" from the USPTO for U.S. application 09/773.672. filing date of 2/2/01, Publication No.: US 2001-0016559 A1, Publication Date: August 23, 2001, Omega-carboxyaryl substituted Dicherel Unesa as Brild Kinsee Inhibitors. I solice.					

Date Considered Signature

Examiner

Exclusive Table 8 reference considered, whether or not calific in in contemporary to the PEPA 00D Date line in tough, databet 7 not in controlled and not considered and processes of the PEPA 00D Date line in though, databet 7 not in controlled and not considered and not of the negation and not considered and not con Alexandria, VA 22313-1450.

Substitute	for form 1449A/PTC)		Complete if Known		
				Application Number	10/788,426	
INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Sheet	32	of	37	Attorney Docket Number	BAYER-0044	
	NFO STAT	NFORMATION STATEMENT B	STATEMENT BY AI	NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Agolication Number First Named Inventor And Unit Examiner Name	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, or						
	P371	A "Nelice of References Cited" from the USPTO for U.S. application 09/7/3,675. filing date of 2/2/01, Publication No : US 2001-001138-A1, Publication Date: August 2, 2001, Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page						
	P372	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935 filling date of 12/22/93, Inhibition Of pS8 Kinase Using Aryl And Hetercaryl Substituted Hetercocyclic Ureas, 1 page						
	P373	A "Notice of Relerences Cited" from the USPTO for U.S. application 09:776,936. filling date of 12/22/98, inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas. 1 page						
	P374	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920, filling date of 2/7/01, inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas, 1 page						
	P375	A "Notice of References Cited" from the USPTO for U.S. application 09/948,915, filling date of 9/10/01, Omega- Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page						
	P376	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226, filing date of 01/11/2002. Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page						
	P376a	Co-pending application Serial No. 09/458,014, filed December 10, 1999, Dumas et al.						
	P377	Abandoned application Serial No. 09/776,935 filed December 22, 1998, Dumas et al.						
	P378	Co-pending application Serial No. 09/776,936 filed December 22, 1993, Miller et al.						
	P379	Issued application Serial No. 09/889,227 filed July 12, 2000, Riedl et al., issued as 7351834, 4/1/2008						
	P380	Co-pending application Senial No. 09/593,647 filed November 27, 2001, Riedl et al., published as 2003- 0181442, 9/25/2003						
	P381	Issued application Serial No. 10/060.395 filed February 1, 2002, Miller et al., patent 7517880, issued 4/14/2009, also published as 2004-0102688, 5/27/2004						
	P382	Issued application Serial No. 10/071,248 filed February 11, 2002, Riedli et al., patent 7528255, issued 5/5/2009, also published as 2003-139005, 7/24/2003						
	P383	Abandoned application Serial No. 10/086,417 filed March 4, 2002, Riedl et al., published as 2003-0105091, 6/5/2003						
	P384 Abandoned application Serial No. 10/125,399 tiled April 19, 2002, Dumas et al., published as 2003-0207914, 11/8/2003							
Examiner Signature		Date Considered						

Signature

EVANINGE final at reference considered, whether or not dation is in conformance with MFPE 600 Draw line through cutton if not in conformance and not considered include copy of this form with need communication to applicant. Applicant's unspec cuttons designation number (soldinosis) see Redis Codes or USETO Pleast Documents at 200 MINES (1990 MINES) and the second of the second

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Beduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

Substitut	e for form 1449A/PTC)		Complete if Known		
				Application Number	10/788,426	
			CLOSURE	Filing Date	March 1, 2004	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	eets as	necessary)	Examiner Name	Heidi L. Reese	
Sheet 33 of 37			37	Attorney Docket Number	BAYER-0044	

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² Cite Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials * number(s), publisher, city and/or country where published Abandoned application Serial No. 10/308,187 filed December 3, 2002, Carrer et al., published as 2003-P385 0232765 12/18/2003 Abandoned application Serial No. 10/361.844 tiled February 11, 2003. Dumas et al., published as 2004-P386 0023961 2/5/2004 Abandoned application Serial No. 10/361.850 filed February 11, 2003, Dumas et al., published as US 2003-P387 0216396. 11/20/2003 Co-pending application Serial No. 10/361.859 filed February 11, 2003, Dumas et al., published as 2003-P388 0216446.11/20/2003 Co-Pending U.S. Patent Application No. 10/895,985 filed July 22, 2004, Boyer et al., published as US 2005-DSSO 0038080, 2/17/2005 Р389Ь Co-Pending U.S. Patent Application No. 11/932.548 filed October 31, 2007. Durnas et al., Co-Pending U.S. Patent Application No. 12/084,662 filed May 7, 2008, Sandner et al., published as 2010-P390 0035888, 2/11/2010 P391 Co-Pending U.S. Patent Application No. 12/086,454 filed June 12, 2008, Weber et al. P391a Co-Pending U.S. Patent Application No. 12/093,515 filed November 13, 2008. Wilhelm et al. P392 Co-Pending U.S. Patent Application No. 12/095,611 filed May 30, 2008, Smith et al. P393 Co-Pending U.S. Patent Application No. 12/158.524 filed June 20, 2008, Smith et al. P394 Co Pending U.S. Patent Application No. 12/294,979 filed September 29, 2008, Wilhelm et al. P394a Co Pending U.S. Patent Application No. 12/421,690 filed April 10, 2009. Dumas et al.,

Examiner Signature		Date Considered						
"EYAMINED Initial if reference consistent whether or not citation in in conformance with MPER 800. Draw line through citation if not in conformance and not considered								

Co Pending U.S. Patent Application No. 12/444,974 filed April 9, 2009. Grunenberg et al.

P395

"EXAMINE!" Inhalf in reference considered, whether or not delation is in conformance with MEPF 200 Date line through clatter in red in conformance and of considered measurability of the PEPF 2010 4. "Early Delation in a conformance and of considered measurability of the PEPF 2010 4." Early Delation in the conformance that the period in the Conformance and of the Conformance and the C process) an application Confidentiality is governed by 35 U S C 122 and 37 CFR 114. This collection is estimated to take 2 hours to complete, including gathering, preparing,

and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexand 9, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are requito respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449A/PTC)		Complete if Known		
				Application Number	10/788,426	
			CLOSURE	Filing Date	March 1, 2004	
STA	TEMENT B	ΥΑ	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Shoot 34 of 37				Atternou Deaket Mumber	BAVED-0044	

	NON PATENT LITERATURE DOCUMENTS							
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, brumal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T 2					
	P396	Co-Pending U.S. Patent Application No. 12/514,129 filed May 8, 2009. Grunenberg et al.						
	P397	Co Pending U.S. Patent Application No. 12/514,715 filed May 13, 2009, Sliehl et al.						
	P398	Co Pending U.S. Patent Application No. 12/520,618 filed June 22, 2009, Smith et al.						
	P399	Co-Pending U.S. Patent Application No. 12/520,609 filed June 22, 2009, Smith et al.						
	P400	Co-pending U.S. Patent Application No. 12/523,652 filed July 17, 2009, Wilhelm et al.						
	P401	Co-pending U.S. Patent Application No. 12/523,697 filed July 17, 2009, Wilhelm et al						
	P402	Co-Pending U.S. Patent Application No. 12/628,735 filed December 1, 2009. Dumas et al.						
	P402a	Co-Pending U.S. Patent Application No. 12/692,845 filed January 25, 2010, Dumas et al.						
	P403	Co-Pending Application PCT/US09/61506, filed October 21. 2009, Carol Pena						
	P404	International search report for International Application No. PCT/US98/10375 dated 9/3/98, Inhibition Of p38 Kinase Activity By Anyl Ureas, publication No. 98/52558. publication date 11/26/1998, 1 page						
	P405	International search report for International Application No. PCT/US98/10376 dated 7/30/98, Raf Kinase Inhibitors, publication No. WO 96/52559, publication date 11/26/1996, 1 page						
	P406	International search report for International Application No. PCT/US98/26076 dated 4/2/99, Inhibition Of Rat Kinase Using Substituted Heterocyclic Ureas, publication no. WO 99/32106, publication date 7/1/1999, 2 pages						
	P407	international search report for International Application No PCT/US98/26079 dated 4/12/99, inhibition OI p36 Kinase Activity Using Aryl And Hetercaryl Substituted Heterocyclic Ureas, publication No. WO 99/32110, publication date 71/1/999, 1 page						
	P408	International search report for International Application No. PCT/US98/28080 dated 4/12/99, Inhibition Of p38 Kinase Using Substituted Heterocyclic Ureas, publication No. WO 99/32111, publication date 7/1/1999, 1 page						

Signature Considered

Date

Examiner

Consideration

Change of the form with neal communication to applicant 3 registration is in conformance with MFEP 600 Draw line through citation if not in conformance and not considered include copy of the form with neal communication to applicant 3 registration super citation designation number (spoticing). See finded Coded or USEPTO Patient Documents at war of the registration of the Engineer registration of the Code of USEPTO Patient Documents and war of the registration of the Engineer Registration o

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Beduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
┖	Sheet	35	of	37	Attorney Docket Number	BAYER-0044	

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² Cite Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials * number(s), publisher, city and/or country where published International search report for International Application No. PCT/US98/26081 dated 4/2/99, INHIBITION OF P409 RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS. publication No. WO 99/32436, publication date 7/1/1999, 1 page International search report to: International Application No PCT/US98/26082 dated 5/12/99, Inhibition Of Rat P410 Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 99/32455, publication International search report for International Application No. PCT/US98/27265, dated 3/2/99, Inhibition of p38 P411 kinase using symmetrical and unsymmetrical diphenyl ureas, publication No. WO 99/32463, publication date International search report for International Application No. PCT/US00/00648 dated 6/29/00. Omega P412 Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase inhibitors, publication No. WO 00/42012 A1. publication date 7/20/2000, 2 pages International search report for International Application No. PCT/US00/00768 dated 5/16/00, Omega-Carboxy D413 Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication No. WO 00/41698 A1, publication date 7/20/2000, 1 page international search report for International Application No. PCT/US02/12064 dated 9/20/02, HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS, publication No Pasa 02/085859, publication date 10/31/2002 2 pages International search report for International Application No. PCT/US02/12066 dated 9/27/02, Inhibition Of Raf P415 Kinase Quinolyl, Isoquinolyl Or Pyridyl Uress, publication No. 02/085857, publication date 10/31/2002, 2 pages Supplemental search report from the EPO for European application EP 98963809.3 dated 3/30/01, Inhibition C/I P416 Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, publication No. 1049664 nublication date 7/1/1999, granted 3/16/2005, 4 pages Supplemental search report from the EPO for European application EP 98963810.1 dated 12/21/00, Inhibition D417 Ot Rat Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. 1056725, publication date 7/1/1999, granted 6/7/2006, 4 pages Supplemental search report from the EPO for European application EP 98965981.8 dated 12/21/00 inhibition D418 Of Raf Kinase Using Substituted Heterocyclic Ureas, publication No. 1047418, publication date 7/1/1999, granted 7/27/2005 8 pages Supplemental search report from the EPO for European application EP 00903239.2 dated 8/7/02, Omega P410 Carboxyaryi Substituted Diphenyl Ureas As Raf Kinase Inhibitors, publication no EP 1140840, published 7/20/2000, granted 3/22/2006, 6 pages Supplemental search report from the EPO for European application EP 00908697.1 dated 2/7/05, Omega P420 Carboxyaryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication no. EP 1158985, 7/20/2000, 9 P431 English abstract of JP 10-306078, 1998-11-17, Patent Abstracts of Japan, 2 pages P432 English abstract of JP 08-301841, 1996-11-19, Patent Abstracts of Japan, 2 pages

Examiner Date Considered Signature "EXAMINE: Table I reference considered, whether or not clation in notiference, with IMEPS 600 thew line through violation if not in continuous and not considered included copy of the time of the price of the price

process) an application Confidentiality is governed by 35 U S C 122 and 37 CFR 114. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. A VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria VA 22313-1450

Approved for use through 11/30/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known 10/788,426 Application Number INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT First Named Inventor Jacques Dumas Art Unit 1625 (Use as many sheets as necessary) Evaminar Mama Heidi L. Reese Sheet of 37 Attorney Docket Number BAYER-0044 36

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² Cite Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials * number(s), publisher, city and/or country where published. P433 English abstract of JP 03-198049, 1991-08-29, Patent Abstracts of Japan, 1 page P434 English abstract of JP 03-144634, 1991-96-20, Patent Abstracts of Japan, 1 page P435 English abstract of JP 03-053247, 1991-03-07, Patent Abstracts of Japan, 1 page P436 English abstract of JP 02-150840, 1990-06-11, Patent Abstracts of Japan, 1 page D437 English abstract of JP 02-108048, 1990-04-19, Patent Abstracts of Japan, 1 page P438 English abstract of JP 02-105146, 1990-04-17, Patent Abstracts of Japan, 1 page P439 English abstract of JP 02-035450, 1990-02-06, Patent Abstracts of Japan, 1 page Paan English abstract of JP 01-200254, 1989-08-11. Patent Abstracts of Japan, 1 page P441 English abstract of JP 01-259360, 1989-10-17. Patent Abstracts of Japan, 2 pages P442 English abstract of JP 01-102461, 1989-04-20, Patent Abstracts of Japan, 1 page P443 English abstract of JP 06-120039, 1994-04-28, Patent Abstracts of Japan, 1 page P444 English abstract of JP 05-180862, 1993-07-23, Patent Abstracts of Japan, 1 page P445 English abstract of JP 05-163170, 1993-96-29, Patent Abstracts of Japan, 1 page Endish abstract of JP 05-077375, 1993-03-30, Patent Abstracts of Japan, 1 page P446

Considered Signature "EXAMINE: Table I reference considered, whether or not clation in notiference, with IMEPS 600 thew line through violation if not in continuous and not considered included copy of the time of the price of the price

Date

Examiner

process) an application Confidentiality is governed by 35 U S C 122 and 37 CFR 114. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. Box 1450, Alexand 9, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	_	Oradi sio i aparilo	111000	20017 EX GI 1000, HO POIGOID GI	o roquiros to rooporta to a concentrario	I TOTT GOOD TO CONTAIN DE VOIG OND CONTO TOTTO	
1	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	ΥΑ	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Γ	Sheet	37	of	37	Attorney Docket Number	BAYER-0044	

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² Cite Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials * number(s), publisher, city and/or country where published P447 English abstract of JP 05-076072, 1993-03-26, Patent Abstracts of Japan, 2 pages Enolish abstract of JP 50-149568 A and JP 56-29871 B. Derwent World Patents Index. Dialog File No. 351. PAAR Acc No. 1488399, 3 pages P449 English abstract of JP 53-086033, 1978-07-29, Patent Abstracts of Japan, 1 page P450 English abstract of JP 54-032468, 1979-03-09, Patent Abstracts of Japan, 1 page D451 English abstract of JP 55-098152, 1980-07-25, Patent Abstracts of Japan, 1 page P452 English abstract of JP 64-009455, 1989-01-12, Patent Abstracts of Japan, 1 page P453 English abstract of JP 02-023337, 1979-03-09, Patent Abstracts of Japan, 2 pages P454 English abstract of EPA 0379915/EP-A1, 1990-08-01, 2 pages P455 English abstract of DD 253997 A, 1988-02-10, 1 page DASS English abstract of DE511468, European Patent Office, 2 pages; 10/30/1930 P457 Co-Pending U.S. Patent Application No. 12/619,913, filed November 17, 2009, Ranges et al T-P3a Arzneimitteltneraple, "Sorafenib" October 6, 2006, Auflage 18498, 7 pages English transistion Examiner Date

Signature Considered "EXAMINER. Initial if reference considered, whether or not obtation is in conformance with MPEP 609. Draw line through obtation if not in conformance and not considered include conv. of this form with next communication to accident. Applicant's unique obtation designation number (optional). See Kinds Codes of USPTO Patent Documents at Include copy of the form with next communication to applicant. Applicant's usuage catation designation number (colorisal). See Kndet Coder of USEPTO Part (Include Country and English of Country and English

were designated on a representation of purpose an extending religious interpretation are under a metal and extending the purpose and the purpo this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450